

## HAPLOTYPES OF THE TNFRSF1A GENE

### FIELD OF THE INVENTION

This invention relates to variation in genes that encode pharmaceutically-important proteins. In particular, this invention provides genetic variants of the human tumor necrosis factor receptor superfamily, member 1A (TNFRSF1A) gene and methods for identifying which variant(s) of this gene is/are possessed by an individual.

### BACKGROUND OF THE INVENTION

Current methods for identifying pharmaceuticals to treat disease often start by identifying, cloning, and expressing an important target protein related to the disease. A determination of whether an agonist or antagonist is needed to produce an effect that may benefit a patient with the disease is then made. Then, vast numbers of compounds are screened against the target protein to find new potential drugs. The desired outcome of this process is a lead compound that is specific for the target, thereby reducing the incidence of the undesired side effects usually caused by activity at non-intended targets. The lead compound identified in this screening process then undergoes further *in vitro* and *in vivo* testing to determine its absorption, disposition, metabolism and toxicological profiles. Typically, this testing involves use of cell lines and animal models with limited, if any, genetic diversity.

What this approach fails to consider, however, is that natural genetic variability exists between individuals in any and every population with respect to pharmaceutically-important proteins, including the protein targets of candidate drugs, the enzymes that metabolize these drugs and the proteins whose activity is modulated by such drug targets. Subtle alteration(s) in the primary nucleotide sequence of a gene encoding a pharmaceutically-important protein may be manifested as significant variation in expression, structure and/or function of the protein. Such alterations may explain the relatively high degree of uncertainty inherent in the treatment of individuals with a drug whose design is based upon a single representative example of the target or enzyme(s) involved in metabolizing the drug. For example, it is well-established that some drugs frequently have lower efficacy in some individuals than others, which means such individuals and their physicians must weigh the possible benefit of a larger dosage against a greater risk of side effects. Also, there is significant variation in how well people metabolize drugs and other exogenous chemicals, resulting in substantial interindividual variation in the toxicity and/or efficacy of such exogenous substances (Evans et al., 1999, *Science* 286:487-491). This variability in efficacy or toxicity of a drug in genetically-diverse patients makes many drugs ineffective or even dangerous in certain groups of the population, leading to the failure of such drugs in clinical trials or their early withdrawal from the market even though they could be highly beneficial for other groups in the population. This problem significantly increases the time and cost of drug discovery and development, which is a matter of great public concern.

It is well-recognized by pharmaceutical scientists that considering the impact of the genetic

variability of pharmaceutically-important proteins in the early phases of drug discovery and development is likely to reduce the failure rate of candidate and approved drugs (Marshall A 1997 *Nature Biotech* **15**:1249-52; Kleyn PW et al. 1998 *Science* **281**: 1820-21; Kola I 1999 *Curr Opin Biotech* **10**:589-92; Hill AVS et al. 1999 in *Evolution in Health and Disease* Stearns SS (Ed.) Oxford University Press, New York, pp 62-76; Meyer U.A. 1999 in *Evolution in Health and Disease* Stearns SS (Ed.) Oxford University Press, New York, pp 41-49; Kalow W et al. 1999 *Clin. Pharm. Therap.* **66**:445-7; Marshall, E 1999 *Science* **284**:406-7; Judson R et al. 2000 *Pharmacogenomics* **1**:1-12; Roses AD 2000 *Nature* **405**:857-65). However, in practice this has been difficult to do, in large part because of the time and cost required for discovering the amount of genetic variation that exists in the population (Chakravarti A 1998 *Nature Genet* **19**:216-7; Wang DG et al 1998 *Science* **280**:1077-82; Chakravarti A 1999 *Nat Genet* **21**:56-60 (suppl); Stephens JC 1999 *Mol. Diagnosis* **4**:309-317; Kwok PY and Gu S 1999 *Mol. Med. Today* **5**:538-43; Davidson S 2000 *Nature Biotech* **18**:1134-5).

The standard for measuring genetic variation among individuals is the haplotype, which is the ordered combination of polymorphisms in the sequence of each form of a gene that exists in the population. Because haplotypes represent the variation across each form of a gene, they provide a more accurate and reliable measurement of genetic variation than individual polymorphisms. For example, while specific variations in gene sequences have been associated with a particular phenotype such as disease susceptibility (Roses AD *supra*; Ulbrecht M et al. 2000 *Am J Respir Crit Care Med* **161**: 469-74) and drug response (Wolfe CR et al. 2000 *BMJ* **320**:987-90; Dahl BS 1997 *Acta Psychiatr Scand* **96** (Suppl 391): 14-21), in many other cases an individual polymorphism may be found in a variety of genomic backgrounds, i.e., different haplotypes, and therefore shows no definitive coupling between the polymorphism and the causative site for the phenotype (Clark AG et al. 1998 *Am J Hum Genet* **63**:595-612; Ulbrecht M et al. 2000 *supra*; Drysdale et al. 2000 *PNAS* **97**:10483-10488). Thus, there is an unmet need in the pharmaceutical industry for information on what haplotypes exist in the population for pharmaceutically-important genes. Such haplotype information would be useful in improving the efficiency and output of several steps in the drug discovery and development process, including target validation, identifying lead compounds, and early phase clinical trials (Marshall et al., *supra*).

One pharmaceutically-important gene for the treatment of tumors, as well as inflammatory and immunological disorders, is the tumor necrosis factor receptor superfamily, member 1A (TNFRSF1A) gene or its encoded product. The ligand for TNFRSF1A is tumor necrosis factor (TNF) which is secreted by macrophages, monocytes, neutrophils, T-cells and NK cells when they are stimulated. Two types of TNF are known, TNF alpha and TNF beta. TNFRSF1A, also referred to as Tumor Necrosis Factor Receptor 1 (TNFR1), is a 55kDa protein that binds to both TNF alpha and beta (Hohmann et al., *J. Biol. Chem.* **264**:14927-14934, 1989). TNF exerts a spectrum of biological effects by binding to the TNFRSF1A receptor. Due to its cytotoxic and cytostatic effects, TNF can destroy the blood vessels in malignant tumors and can serve as an anti-tumor agent (Bruce et al., *Nature Med.* **2**: 788-794, 1996). TNF also mediates part of cell mediated immunity and confers resistance to infection caused by the

facultative bacterium *Listeria monocytogenes* (Rothe et al., *Nature* 364; 798-802, 1993).

The C-terminal region of TNFRSF1A contains a death domain that interacts with MAP kinase-Activating Death Domain (MADD), a protein that acts as a mediator of the down stream effects of TNF signaling. MADD activates the MAP kinases and induces the phosphorylation of cytosolic

5 phospholipase A2 (Schievella et al., *J Biol. Chem.* 272: 12069-75, 1997). Mutations in the extracellular domain of TNFRSF1A are associated with a periodic fever syndrome; autosomal dominant periodic fever syndrome, also known as TNF Receptor-Associated Periodic Syndromes (TRAPS), is characterized by episodes of fever and severe localized inflammation (Aksentijevich et al. *Am J. Hum. Genet.* 2001, 69(2):301-14).

10 The tumor necrosis factor receptor superfamily, member 1A gene is located on chromosome 12p13.2 and contains 10 exons that encode a 455 amino acid protein. A reference sequence for the TNFRSF1A gene is shown in the contiguous lines of Figure 1 (Genaissance Reference No. 7918690; SEQ ID NO: 1). Reference sequences for the coding sequence (GenBank Accession No. XM\_006950.1) and protein are shown in Figures 2 (SEQ ID NO: 2) and 3 (SEQ ID NO: 3), respectively.

15 A large number of single nucleotide polymorphisms in the TNFRSF1A coding sequence result in missense protein mutations. Six such missense mutations of this receptor have been studied in detail, of which five disrupt the conserved extracellular disulfide bonds (McDermott et al., *Cell* 97: 133-144, 1999). These mutations in the processed TNFRSF1A protein are Cys30Arg, Cys33Tyr, Thr50Met, Cys52Phe, Cys88Tyr and Cys88Arg. Membrane TNFRSF1A is regulated in part by metalloprotease-mediated cleavage where shedding of receptors followed by their clearance from the membrane takes place. Leukocytes bearing the Cys52Phe mutation showed increased levels of membrane receptor and diminished cleavage following stimulation. As a result, the down regulation of the membrane TNFRSF1A is impaired and the amount of soluble receptors in the cell decreases. This condition is manifested as an autoinflammatory syndrome (McDermott et al., *Cell* 97: 133-144, 1999).

20 Because of the potential for variation in the TNFRSF1A gene to affect the expression and function of the encoded protein, it would be useful to know whether additional polymorphisms exist in the TNFRSF1A gene, as well as how such polymorphisms are combined in different copies of the gene. Such information could be applied for studying the biological function of TNFRSF1A as well as in identifying drugs targeting this protein for the treatment of disorders related to its abnormal expression or function.

## SUMMARY OF THE INVENTION

Accordingly, the inventors herein have discovered 7 novel polymorphic sites in the TNFRSF1A gene. These polymorphic sites (PS) correspond to the following nucleotide positions in Figure 1: 3102 35 (PS1), 3603 (PS4), 14824 (PS12), 15089 (PS14), 15093 (PS15), 15932 (PS17) and 16165 (PS18). The polymorphisms at these sites are guanine or thymine at PS1, cytosine or guanine at PS4, guanine or

adenine at PS12, cytosine or thymine at PS14, cytosine or thymine at PS15, guanine or adenine at PS17 and guanine or adenine at PS18. In addition, the inventors have determined the identity of the alleles at these sites, as well as at the previously identified sites at nucleotide positions 3409 (PS2), 3438 (PS3), 4054 (PS5), 4082 (PS6), 11998 (PS7), 12356 (PS8), 12397 (PS9), 12489 (PS10), 12653 (PS11), 14990 5 (PS13) and 15529 (PS16), in a human reference population of 79 unrelated individuals self-identified as belonging to one of four major population groups: African descent, Asian, Caucasian and Hispanic/Latino. From this information, the inventors deduced a set of haplotypes and haplotype pairs for PS1-PS18 in the TNFRSF1A gene, which are shown below in Tables 5 and 4, respectively. Each of these TNFRSF1A haplotypes constitutes a code that defines the variant nucleotides that exist in the 10 human population at this set of polymorphic sites in the TNFRSF1A gene. Thus each TNFRSF1A haplotype also represents a naturally-occurring isoform (also referred to herein as an "isogene") of the TNFRSF1A gene. The frequency of each haplotype and haplotype pair within the total reference population and within each of the four major population groups included in the reference population was also determined.

15 Although polymorphic sites PS2, PS3, PS5-PS11, PS13, and PS16 in Table 3 were reported previously by Applicants in WO 00/50436, nothing in that reference discloses or suggests the existence of polymorphic sites PS1, PS4, PS12, PS14, PS15, PS17 or PS18. Consequently, the full set of 18 polymorphic sites was not previously known or suggested, nor were the haplotypes comprising the phased sequence of nucleotides at PS1-PS18 previously known or suggested.

20 Thus, in one embodiment, the invention provides a method, composition and kit for genotyping the TNFRSF1A gene in an individual. The genotyping method comprises identifying the nucleotide pair that is present at one or more polymorphic sites selected from the group consisting of PS1, PS4, PS12, PS14, PS15, PS17 and PS18 in both copies of the TNFRSF1A gene from the individual. A genotyping composition of the invention comprises an oligonucleotide probe or primer which is 25 designed to specifically hybridize to a target region containing, or adjacent to, one of these novel TNFRSF1A polymorphic sites. A genotyping kit of the invention comprises a set of oligonucleotides designed to genotype each of these novel TNFRSF1A polymorphic sites. In a preferred embodiment, the genotyping kit comprises a set of oligonucleotides designed to genotype each of PS1-PS18. The genotyping method, composition, and kit are useful in determining whether an individual has one of the 30 haplotypes in Table 5 below or has one of the haplotype pairs in Table 4 below.

The invention also provides a method for haplotyping the TNFRSF1A gene in an individual. In one embodiment, the haplotyping method comprises determining, for one copy of the TNFRSF1A gene, the identity of the nucleotide at one or more polymorphic sites selected from the group consisting of PS1, PS4, PS12, PS14, PS15, PS17 and PS18. In another embodiment, the haplotyping method 35 comprises determining whether one copy of the individual's TNFRSF1A gene is defined by one of the TNFRSF1A haplotypes shown in Table 5, below, or a sub-haplotype thereof. In a preferred embodiment, the haplotyping method comprises determining whether both copies of the individual's

TNFRSF1A gene are defined by one of the TNFRSF1A haplotype pairs shown in Table 4 below, or a sub-haplotype pair thereof. Establishing the TNFRSF1A haplotype or haplotype pair of an individual is useful for improving the efficiency and reliability of several steps in the discovery and development of drugs for treating diseases associated with TNFRSF1A activity, e.g., tumors, inflammatory disorders,  
5 and immunological disorders.

For example, the haplotyping method can be used by the pharmaceutical research scientist to validate TNFRSF1A as a candidate target for treating a specific condition or disease predicted to be associated with TNFRSF1A activity. Determining for a particular population the frequency of one or more of the individual TNFRSF1A haplotypes or haplotype pairs described herein will facilitate a  
10 decision on whether to pursue TNFRSF1A as a target for treating the specific disease of interest. In particular, if variable TNFRSF1A activity is associated with the disease, then one or more TNFRSF1A haplotypes or haplotype pairs will be found at a higher frequency in disease cohorts than in appropriately genetically matched controls. Conversely, if each of the observed TNFRSF1A haplotypes are of similar frequencies in the disease and control groups, then it may be inferred that variable  
15 TNFRSF1A activity has little, if any, involvement with that disease. In either case, the pharmaceutical research scientist can, without *a priori* knowledge as to the phenotypic effect of any TNFRSF1A haplotype or haplotype pair, apply the information derived from detecting TNFRSF1A haplotypes in an individual to decide whether modulating TNFRSF1A activity would be useful in treating the disease.

The claimed invention is also useful in screening for compounds targeting TNFRSF1A to treat a specific condition or disease predicted to be associated with TNFRSF1A activity. For example, detecting which of the TNFRSF1A haplotypes or haplotype pairs disclosed herein are present in individual members of a population with the specific disease of interest enables the pharmaceutical scientist to screen for a compound(s) that displays the highest desired agonist or antagonist activity for each of the TNFRSF1A isoforms present in the disease population, or for only the most frequent  
25 TNFRSF1A isoforms present in the disease population. Thus, without requiring any *a priori* knowledge of the phenotypic effect of any particular TNFRSF1A haplotype or haplotype pair, the claimed haplotyping method provides the scientist with a tool to identify lead compounds that are more likely to show efficacy in clinical trials.

Haplotyping the TNFRSF1A gene in an individual is also useful in the design of clinical trials  
30 of candidate drugs for treating a specific condition or disease predicted to be associated with TNFRSF1A activity. For example, instead of randomly assigning patients with the disease of interest to the treatment or control group as is typically done now, determining which of the TNFRSF1A haplotype(s) disclosed herein are present in individual patients enables the pharmaceutical scientist to distribute TNFRSF1A haplotypes and/or haplotype pairs evenly to treatment and control groups,  
35 thereby reducing the potential for bias in the results that could be introduced by a larger frequency of a TNFRSF1A haplotype or haplotype pair that is associated with response to the drug being studied in the trial, even if this association was previously unknown. Thus, by practicing the claimed invention, the

scientist can more confidently rely on the information learned from the trial, without first determining the phenotypic effect of any TNFRSF1A haplotype or haplotype pair.

In another embodiment, the invention provides a method for identifying an association between a trait and a TNFRSF1A genotype, haplotype, or haplotype pair for one or more of the novel polymorphic sites described herein. The method comprises comparing the frequency of the TNFRSF1A genotype, haplotype, or haplotype pair in a population exhibiting the trait with the frequency of the TNFRSF1A genotype or haplotype in a reference population. A higher frequency of the TNFRSF1A genotype, haplotype, or haplotype pair in the trait population than in the reference population indicates the trait is associated with the TNFRSF1A genotype, haplotype, or haplotype pair.

10 In preferred embodiments, the trait is susceptibility to a disease, severity of a disease, the staging of a disease or response to a drug. In a particularly preferred embodiment, the TNFRSF1A haplotype is selected from the haplotypes shown in Table 5, or a sub-haplotype thereof. Such methods have applicability in developing diagnostic tests and therapeutic treatments for tumors, inflammatory disorders, and immunological disorders.

15 In yet another embodiment, the invention provides an isolated polynucleotide comprising a nucleotide sequence which is a polymorphic variant of a reference sequence for the TNFRSF1A gene or a fragment thereof. The reference sequence comprises the contiguous sequences shown in Figure 1 and the polymorphic variant comprises at least one polymorphism selected from the group consisting of thymine at PS1, guanine at PS4, adenine at PS12, thymine at PS14, thymine at PS15, adenine at PS17 and adenine at PS18. In a preferred embodiment, the polymorphic variant comprises one or more additional polymorphisms selected from the group consisting of guanine at PS2, guanine at PS3, guanine at PS5, adenine at PS6, thymine at PS7, adenine at PS8, cytosine at PS9, thymine at PS10, cytosine at PS11, guanine at PS13 and cytosine at PS16.

20 A particularly preferred polymorphic variant is an isogene of the TNFRSF1A gene. A TNFRSF1A isogene of the invention comprises guanine or thymine at PS1, thymine or guanine at PS2, adenine or guanine at PS3, cytosine or guanine at PS4, adenine or guanine at PS5, guanine or adenine at PS6, cytosine or thymine at PS7, guanine or adenine at PS8, thymine or cytosine at PS9, cytosine or thymine at PS10, thymine or cytosine at PS11, guanine or adenine at PS12, adenine or guanine at PS13, cytosine or thymine at PS14, cytosine or thymine at PS15, thymine or cytosine at PS16, guanine or adenine at PS17 and guanine or adenine at PS18. The invention also provides a collection of TNFRSF1A isogenes, referred to herein as a TNFRSF1A genome anthology.

25 In another embodiment, the invention provides a polynucleotide comprising a polymorphic variant of a reference sequence for a TNFRSF1A cDNA or a fragment thereof. The reference sequence comprises SEQ ID NO:2 (Fig.2) and the polymorphic cDNA comprises adenine at a position corresponding to nucleotide 935. In a preferred embodiment, the polymorphic variant comprises one or more additional polymorphisms selected from the group consisting of thymine at a position corresponding to nucleotide 224, adenine at a position corresponding to nucleotide 362 and cytosine at

a position corresponding to nucleotide 403. A particularly preferred polymorphic cDNA variant comprises the coding sequence of a TNFRSF1A isogene defined by haplotypes 8, 9, 14, 17, and 19.

Polynucleotides complementary to these TNFRSF1A genomic and cDNA variants are also provided by the invention. It is believed that polymorphic variants of the TNFRSF1A gene will be useful in studying the expression and function of TNFRSF1A, and in expressing TNFRSF1A protein for use in screening for candidate drugs to treat diseases related to TNFRSF1A activity.

In other embodiments, the invention provides a recombinant expression vector comprising one of the polymorphic genomic and cDNA variants operably linked to expression regulatory elements as well as a recombinant host cell transformed or transfected with the expression vector. The recombinant vector and host cell may be used to express TNFRSF1A for protein structure analysis and drug binding studies.

In yet another embodiment, the invention provides a polypeptide comprising a polymorphic variant of a reference amino acid sequence for the TNFRSF1A protein. The reference amino acid sequence comprises SEQ ID NO:3 (Fig.3) and the polymorphic variant comprises lysine at a position corresponding to amino acid position 312. In some embodiments, the polymorphic variant also comprises at least one variant amino acid selected from the group consisting of leucine at a position corresponding to amino acid position 75, glutamine at a position corresponding to amino acid position 121 and histidine at a position corresponding to amino acid position 135. A polymorphic variant of TNFRSF1A is useful in studying the effect of the variation on the biological activity of TNFRSF1A as well as on the binding affinity of candidate drugs targeting TNFRSF1A for the treatment of tumors, inflammatory disorders, and immunological disorders.

The present invention also provides antibodies that recognize and bind to the above polymorphic TNFRSF1A protein variant. Such antibodies can be utilized in a variety of diagnostic and prognostic formats and therapeutic methods.

The present invention also provides nonhuman transgenic animals comprising one or more of the TNFRSF1A polymorphic genomic variants described herein and methods for producing such animals. The transgenic animals are useful for studying expression of the TNFRSF1A isogenes *in vivo*, for *in vivo* screening and testing of drugs targeted against TNFRSF1A protein, and for testing the efficacy of therapeutic agents and compounds for tumors, inflammatory disorders, and immunological disorders in a biological system.

The present invention also provides a computer system for storing and displaying polymorphism data determined for the TNFRSF1A gene. The computer system comprises a computer processing unit; a display; and a database containing the polymorphism data. The polymorphism data includes one or more of the following: the polymorphisms, the genotypes, the haplotypes, and the haplotype pairs identified for the TNFRSF1A gene in a reference population. In a preferred embodiment, the computer system is capable of producing a display showing TNFRSF1A haplotypes organized according to their evolutionary relationships.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 illustrates a reference sequence for the TNFRSF1A gene (Genaissance Reference No. 7918690; contiguous lines), with the start and stop positions of each region of coding sequence indicated with a bracket ([ or ]) and the numerical position below the sequence and the polymorphic site(s) and polymorphism(s) identified by Applicants in a reference population indicated by the variant nucleotide positioned below the polymorphic site in the sequence. SEQ ID NO:1 is equivalent to Figure 1, with the two alternative allelic variants of each polymorphic site indicated by the appropriate nucleotide symbol (R= G or A, Y= T or C, M= A or C, K= G or T, S= G or C, and W= A or T; WIPO standard ST.25). SEQ ID NO:41 is a modified version of SEQ ID NO:1 that shows the context sequence of each polymorphic site, PS1-PS18, in a uniform format to facilitate electronic searching. For each polymorphic site, SEQ ID NO:41 contains a block of 60 bases of the nucleotide sequence encompassing the centrally-located polymorphic site at the 30<sup>th</sup> position, followed by 60 bases of unspecified sequence to represent that each PS is separated by genomic sequence whose composition is defined elsewhere herein.

Figure 2 illustrates a reference sequence for the TNFRSF1A coding sequence (contiguous lines; SEQ ID NO:2), with the polymorphic site(s) and polymorphism(s) identified by Applicants in a reference population indicated by the variant nucleotide positioned below the polymorphic site in the sequence.

Figure 3 illustrates a reference sequence for the TNFRSF1A protein (contiguous lines; SEQ ID NO:3), with the variant amino acid(s) caused by the polymorphism(s) of Figure 2 positioned below the polymorphic site in the sequence.

DESCRIPTION OF THE PREFERRED EMBODIMENTS

The present invention is based on the discovery of novel variants of the TNFRSF1A gene. As described in more detail below, the inventors herein discovered 27 isogenes of the TNFRSF1A gene by characterizing the TNFRSF1A gene found in genomic DNAs isolated from an Index Repository that contains immortalized cell lines from one chimpanzee and 93 human individuals. The human individuals included a reference population of 79 unrelated individuals self-identified as belonging to one of four major population groups: Caucasian (21 individuals), African descent (20 individuals), Asian (20 individuals), or Hispanic/Latino (18 individuals). To the extent possible, the members of this reference population were organized into population subgroups by their self-identified ethnogeographic origin as shown in Table 1 below.

Table 1. Population Groups in the Index Repository

Population Group	Population Subgroup	No. of Individuals
African descent		20
	Sierra Leone	1
Asian		20
	Burma	1
	China	3
	Japan	6
	Korea	1
	Philippines	5
	Vietnam	4
Caucasian		21
	British Isles	3
	British Isles/Central	4
	British Isles/Eastern	1
	Central/Eastern	1
	Eastern	3
	Central/Mediterranean	1
	Mediterranean	2
	Scandinavian	2
Hispanic/Latino		18
	Caribbean	8
	Caribbean (Spanish Descent)	2
	Central American (Spanish Descent)	1
	Mexican American	4
	South American (Spanish Descent)	3

In addition, the Index Repository contains three unrelated indigenous American Indians (one from each of North, Central and South America), one three-generation Caucasian family (from the CEPH Utah cohort) and one two-generation African-American family.

The TNFRSF1A isogenes present in the human reference population are defined by haplotypes for 18 polymorphic sites in the TNFRSF1A gene, 7 of which are believed to be novel. The TNFRSF1A polymorphic sites identified by the inventors are referred to as PS1-PS18 to designate the order in which they are located in the gene (see Table 3 below), with the novel polymorphic sites referred to as PS1, PS4, PS12, PS14, PS15, PS17 and PS18. Using the genotypes identified in the Index Repository for PS1-PS18 and the methodology described in the Examples below, the inventors herein also determined the pair of haplotypes for the TNFRSF1A gene present in individual human members of this repository. The human genotypes and haplotypes found in the repository for the TNFRSF1A gene include those shown in Tables 4 and 5, respectively. The polymorphism and haplotype data disclosed herein are useful for validating whether TNFRSF1A is a suitable target for drugs to treat tumors, inflammatory disorders, and immunological disorders, screening for such drugs and reducing bias in clinical trials of such drugs.

In the context of this disclosure, the following terms shall be defined as follows unless otherwise indicated:

Allele - A particular form of a genetic locus, distinguished from other forms by its particular

45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

nucleotide sequence.

**Candidate Gene** – A gene which is hypothesized to be responsible for a disease, condition, or the response to a treatment, or to be correlated with one of these.

**Gene** - A segment of DNA that contains all the information for the regulated biosynthesis of an RNA product, including promoters, exons, introns, and other untranslated regions that control expression.

**Genotype** – An unphased 5' to 3' sequence of nucleotide pair(s) found at one or more polymorphic sites in a locus on a pair of homologous chromosomes in an individual. As used herein, genotype includes a full-genotype and/or a sub-genotype as described below.

**Full-genotype** – The unphased 5' to 3' sequence of nucleotide pairs found at all polymorphic sites examined herein in a locus on a pair of homologous chromosomes in a single individual.

**Sub-genotype** – The unphased 5' to 3' sequence of nucleotides seen at a subset of the polymorphic sites examined herein in a locus on a pair of homologous chromosomes in a single individual.

**Genotyping** – A process for determining a genotype of an individual.

**Haplotype** – A 5' to 3' sequence of nucleotides found at one or more polymorphic sites in a locus on a single chromosome from a single individual. As used herein, haplotype includes a full-haplotype and/or a sub-haplotype as described below.

**Full-haplotype** – The 5' to 3' sequence of nucleotides found at all polymorphic sites examined herein in a locus on a single chromosome from a single individual.

**Sub-haplotype** – The 5' to 3' sequence of nucleotides seen at a subset of the polymorphic sites examined herein in a locus on a single chromosome from a single individual.

**Haplotype pair** – The two haplotypes found for a locus in a single individual.

**Haplotyping** – A process for determining one or more haplotypes in an individual and includes use of family pedigrees, molecular techniques and/or statistical inference.

**Haplotype data** - Information concerning one or more of the following for a specific gene: a listing of the haplotype pairs in each individual in a population; a listing of the different haplotypes in a population; frequency of each haplotype in that or other populations, and any known associations between one or more haplotypes and a trait.

**Isoform** – A particular form of a gene, mRNA, cDNA or the protein encoded thereby, distinguished from other forms by its particular sequence and/or structure.

**Isogene** – One of the isoforms (e.g., alleles) of a gene found in a population. An isogene (or allele) contains all of the polymorphisms present in the particular isoform of the gene.

**Isolated** – As applied to a biological molecule such as RNA, DNA, oligonucleotide, or protein, isolated means the molecule is substantially free of other biological molecules such as nucleic acids, proteins, lipids, carbohydrates, or other material such as cellular debris and growth media. Generally, the term "isolated" is not intended to refer to a complete absence of such material or to absence of

water, buffers, or salts, unless they are present in amounts that substantially interfere with the methods of the present invention.

**Locus** - A location on a chromosome or DNA molecule corresponding to a gene or a physical or phenotypic feature, where physical features include polymorphic sites.

5       **Naturally-occurring** – A term used to designate that the object it is applied to, e.g., naturally-occurring polynucleotide or polypeptide, can be isolated from a source in nature and which has not been intentionally modified by man.

10      **Nucleotide pair** – The nucleotides found at a polymorphic site on the two copies of a chromosome from an individual.

15      **Phased** – As applied to a sequence of nucleotide pairs for two or more polymorphic sites in a locus, phased means the combination of nucleotides present at those polymorphic sites on a single copy of the locus is known.

20      **Polymorphic site (PS)** – A position on a chromosome or DNA molecule at which at least two alternative sequences are found in a population.

25      **Polymorphic variant** – A gene, mRNA, cDNA, polypeptide or peptide whose nucleotide or amino acid sequence varies from a reference sequence due to the presence of a polymorphism in the gene.

30      **Polymorphism** – The sequence variation observed in an individual at a polymorphic site. Polymorphisms include nucleotide substitutions, insertions, deletions and microsatellites and may, but need not, result in detectable differences in gene expression or protein function.

35      **Polymorphism data** – Information concerning one or more of the following for a specific gene: location of polymorphic sites; sequence variation at those sites; frequency of polymorphisms in one or more populations; the different genotypes and/or haplotypes determined for the gene; frequency of one or more of these genotypes and/or haplotypes in one or more populations; any known association(s) between a trait and a genotype or a haplotype for the gene.

40      **Polymorphism Database** – A collection of polymorphism data arranged in a systematic or methodical way and capable of being individually accessed by electronic or other means.

45      **Polynucleotide** – A nucleic acid molecule comprised of single-stranded RNA or DNA or comprised of complementary, double-stranded DNA.

50      **Population Group** – A group of individuals sharing a common ethnogeographic origin.

55      **Reference Population** – A group of subjects or individuals who are predicted to be representative of the genetic variation found in the general population. Typically, the reference population represents the genetic variation in the population at a certainty level of at least 85%, preferably at least 90%, more preferably at least 95% and even more preferably at least 99%.

60      **Single Nucleotide Polymorphism (SNP)** – Typically, the specific pair of nucleotides observed at a single polymorphic site. In rare cases, three or four nucleotides may be found.

65      **Subject** – A human individual whose genotypes or haplotypes or response to treatment or

15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
2210  
2211  
2212  
2213  
2214  
2215  
2216  
2217  
2218  
2219  
22110  
22111  
22112  
22113  
22114  
22115  
22116  
22117  
22118  
22119  
221110  
221111  
221112  
221113  
221114  
221115  
221116  
221117  
221118  
221119  
2211110  
2211111  
2211112  
2211113  
2211114  
2211115  
2211116  
2211117  
2211118  
2211119  
22111110  
22111111  
22111112  
22111113  
22111114  
22111115  
22111116  
22111117  
22111118  
22111119  
221111110  
221111111  
221111112  
221111113  
221111114  
221111115  
221111116  
221111117  
221111118  
221111119  
2211111110  
2211111111  
2211111112  
2211111113  
2211111114  
2211111115  
2211111116  
2211111117  
2211111118  
2211111119  
22111111110  
22111111111  
22111111112  
22111111113  
22111111114  
22111111115  
22111111116  
22111111117  
22111111118  
22111111119  
221111111110  
221111111111  
221111111112  
221111111113  
221111111114  
221111111115  
221111111116  
221111111117  
221111111118  
221111111119  
2211111111110  
2211111111111  
2211111111112  
2211111111113  
2211111111114  
2211111111115  
2211111111116  
2211111111117  
2211111111118  
2211111111119  
22111111111110  
22111111111111  
22111111111112  
22111111111113  
22111111111114  
22111111111115  
22111111111116  
22111111111117  
22111111111118  
22111111111119  
221111111111110  
221111111111111  
221111111111112  
221111111111113  
221111111111114  
221111111111115  
221111111111116  
221111111111117  
221111111111118  
221111111111119  
2211111111111110  
2211111111111111  
2211111111111112  
2211111111111113  
2211111111111114  
2211111111111115  
2211111111111116  
2211111111111117  
2211111111111118  
2211111111111119  
22111111111111110  
22111111111111111  
22111111111111112  
22111111111111113  
22111111111111114  
22111111111111115  
22111111111111116  
22111111111111117  
22111111111111118  
22111111111111119  
221111111111111110  
221111111111111111  
221111111111111112  
221111111111111113  
221111111111111114  
221111111111111115  
221111111111111116  
221111111111111117  
221111111111111118  
221111111111111119  
2211111111111111110  
2211111111111111111  
2211111111111111112  
2211111111111111113  
2211111111111111114  
2211111111111111115  
2211111111111111116  
2211111111111111117  
2211111111111111118  
2211111111111111119  
22111111111111111110  
22111111111111111111  
22111111111111111112  
22111111111111111113  
22111111111111111114  
22111111111111111115  
22111111111111111116  
22111111111111111117  
22111111111111111118  
22111111111111111119  
221111111111111111110  
221111111111111111111  
221111111111111111112  
221111111111111111113  
221111111111111111114  
221111111111111111115  
221111111111111111116  
221111111111111111117  
221111111111111111118  
221111111111111111119  
2211111111111111111110  
2211111111111111111111  
2211111111111111111112  
2211111111111111111113  
2211111111111111111114  
2211111111111111111115  
2211111111111111111116  
2211111111111111111117  
2211111111111111111118  
2211111111111111111119  
22111111111111111111110  
22111111111111111111111  
22111111111111111111112  
22111111111111111111113  
22111111111111111111114  
22111111111111111111115  
22111111111111111111116  
22111111111111111111117  
22111111111111111111118  
22111111111111111111119  
221111111111111111111110  
221111111111111111111111  
221111111111111111111112  
221111111111111111111113  
221111111111111111111114  
221111111111111111111115  
221111111111111111111116  
221111111111111111111117  
221111111111111111111118  
221111111111111111111119  
2211111111111111111111110  
2211111111111111111111111  
2211111111111111111111112  
2211111111111111111111113  
2211111111111111111111114  
2211111111111111111111115  
2211111111111111111111116  
2211111111111111111111117  
2211111111111111111111118  
2211111111111111111111119  
22111111111111111111111110  
22111111111111111111111111  
22111111111111111111111112  
22111111111111111111111113  
22111111111111111111111114  
22111111111111111111111115  
22111111111111111111111116  
22111111111111111111111117  
22111111111111111111111118  
22111111111111111111111119  
221111111111111111111111110  
221111111111111111111111111  
221111111111111111111111112  
221111111111111111111111113  
221111111111111111111111114  
221111111111111111111111115  
221111111111111111111111116  
221111111111111111111111117  
221111111111111111111111118  
221111111111111111111111119  
2211111111111111111111111110  
2211111111111111111111111111  
2211111111111111111111111112  
2211111111111111111111111113  
2211111111111111111111111114  
2211111111111111111111111115  
2211111111111111111111111116  
2211111111111111111111111117  
2211111111111111111111111118  
2211111111111111111111111119  
22111111111111111111111111110  
22111111111111111111111111111  
22111111111111111111111111112  
22111111111111111111111111113  
22111111111111111111111111114  
22111111111111111111111111115  
22111111111111111111111111116  
22111111111111111111111111117  
22111111111111111111111111118  
22111111111111111111111111119  
221111111111111111111111111110  
221111111111111111111111111111  
221111111111111111111111111112  
221111111111111111111111111113  
221111111111111111111111111114  
221111111111111111111111111115  
221111111111111111111111111116  
221111111111111111111111111117  
221111111111111111111111111118  
221111111111111111111111111119  
2211111111111111111111111111110  
2211111111111111111111111111111  
2211111111111111111111111111112  
2211111111111111111111111111113  
2211111111111111111111111111114  
2211111111111111111111111111115  
2211111111111111111111111111116  
2211111111111111111111111111117  
2211111111111111111111111111118  
2211111111111111111111111111119  
22111111111111111111111111111110  
22111111111111111111111111111111  
22111111111111111111111111111112  
22111111111111111111111111111113  
22111111111111111111111111111114  
22111111111111111111111111111115  
22111111111111111111111111111116  
22111111111111111111111111111117  
22111111111111111111111111111118  
22111111111111111111111111111119  
221111111111111111111111111111110  
221111111111111111111111111111111  
221111111111111111111111111111112  
221111111111111111111111111111113  
221111111111111111111111111111114  
221111111111111111111111111111115  
221111111111111111111111111111116  
221111111111111111111111111111117  
221111111111111111111111111111118  
221111111111111111111111111111119  
2211111111111111111111111111111110  
2211111111111111111111111111111111  
2211111111111111111111111111111112  
2211111111111111111111111111111113  
2211111111111111111111111111111114  
2211111111111111111111111111111115  
2211111111111111111111111111111116  
2211111111111111111111111111111117  
2211111111111111111111111111111118  
2211111111111111111111111111111119  
22111111111111111111111111111111110  
22111111111111111111111111111111111  
22111111111111111111111111111111112  
22111111111111111111111111111111113  
22111111111111111111111111111111114  
22111111111111111111111111111111115  
22111111111111111111111111111111116  
22111111111111111111111111111111117  
22111111111111111111111111111111118  
22111111111111111111111111111111119  
221111111111111111111111111111111110  
221111111111111111111111111111111111  
221111111111111111111111111111111112  
221111111111111111111111111111111113  
221111111111111111111111111111111114  
221111111111111111111111111111111115  
221111111111111111111111111111111116  
221111111111111111111111111111111117  
221111111111111111111111111111111118  
221111111111111111111111111111111119  
2211111111111111111111111111111111110  
2211111111111111111111111111111111111  
2211111111111111111111111111111111112  
2211111111111111111111111111111111113  
2211111111111111111111111111111111114  
2211111111111111111111111111111111115  
2211111111111111111111111111111111116  
2211111111111111111111111111111111117  
2211111111111111111111111111111111118  
2211111111111111111111111111111111119  
22111111111111111111111111111111111110  
22111111111111111111111111111111111111  
22111111111111111111111111111111111112  
22111111111111111111111111111111111113  
22111111111111111111111111111111111114  
22111111111111111111111111111111111115  
22111111111111111111111111111111111116  
22111111111111111111111111111111111117  
22111111111111111111111111111111111118  
22111111111111111111111111111111111119  
221111111111111111111111111111111111110  
2211111111111111111111111111111111111111  
2211111111111111111111111111111111111112  
2211111111111111111111111111111111111113  
2211111111111111111111111111111111111114  
2211111111111111111111111111111111111115  
2211111111111111111111111111111111111116  
2211111111111111111111111111111111111117  
2211111111111111111111111111111111111118  
2211111111111111111111111111111111111119  
22111111111111111111111111111111111111110  
22111111111111111111111111111111111111111  
22111111111111111111111111111111111111112  
22111111111111111111111111111111111111113  
22111111111111111111111111111111111111114  
22111111111111111111111111111111111111115  
22111111111111111111111111111111111111116  
22111111111111111111111111111111111111117  
22111111111111111111111111111111111111118  
22111111111111111111111111111111111111119  
221111111111111111111111111111111111111110  
2211  
221111111111111111111111111111111111111112  
221111111111111111111111111111111111111113  
221111111111111111111111111111111111111114  
221111111111111111

disease state are to be determined.

**Treatment** - A stimulus administered internally or externally to a subject.

**Unphased** – As applied to a sequence of nucleotide pairs for two or more polymorphic sites in a locus, unphased means the combination of nucleotides present at those polymorphic sites on a single copy of the locus is not known.

As discussed above, information on the identity of genotypes and haplotypes for the TNFRSF1A gene of any particular individual as well as the frequency of such genotypes and haplotypes in any particular population of individuals is useful for a variety of drug discovery and development applications. Thus, the invention also provides compositions and methods for detecting the novel TNFRSF1A polymorphisms, haplotypes and haplotype pairs identified herein.

The compositions comprise at least one oligonucleotide for detecting the variant nucleotide or nucleotide pair located at a novel TNFRSF1A polymorphic site in one copy or two copies of the TNFRSF1A gene. Such oligonucleotides are referred to herein as TNFRSF1A haplotyping oligonucleotides or genotyping oligonucleotides, respectively, and collectively as TNFRSF1A oligonucleotides. In one embodiment, a TNFRSF1A haplotyping or genotyping oligonucleotide is a probe or primer capable of hybridizing to a target region that contains, or that is located close to, one of the novel polymorphic sites described herein.

As used herein, the term “oligonucleotide” refers to a polynucleotide molecule having less than about 100 nucleotides. A preferred oligonucleotide of the invention is 10 to 35 nucleotides long. More preferably, the oligonucleotide is between 15 and 30, and most preferably, between 20 and 25 nucleotides in length. The exact length of the oligonucleotide will depend on many factors that are routinely considered and practiced by the skilled artisan. The oligonucleotide may be comprised of any phosphorylation state of ribonucleotides, deoxyribonucleotides, and acyclic nucleotide derivatives, and other functionally equivalent derivatives. Alternatively, oligonucleotides may have a phosphate-free backbone, which may be comprised of linkages such as carboxymethyl, acetamide, carbamate, polyamide (peptide nucleic acid (PNA)) and the like (Varma, R. in Molecular Biology and Biotechnology, A Comprehensive Desk Reference, Ed. R. Meyers, VCH Publishers, Inc. (1995), pages 617-620). Oligonucleotides of the invention may be prepared by chemical synthesis using any suitable methodology known in the art, or may be derived from a biological sample, for example, by restriction digestion. The oligonucleotides may be labeled, according to any technique known in the art, including use of radiolabels, fluorescent labels, enzymatic labels, proteins, haptens, antibodies, sequence tags and the like.

Haplotyping or genotyping oligonucleotides of the invention must be capable of specifically hybridizing to a target region of a TNFRSF1A polynucleotide. Preferably, the target region is located in a TNFRSF1A isogene. As used herein, specific hybridization means the oligonucleotide forms an anti-parallel double-stranded structure with the target region under certain hybridizing conditions, while failing to form such a structure when incubated with another region in the TNFRSF1A polynucleotide

or with a non-TNFRSF1A polynucleotide under the same hybridizing conditions. Preferably, the oligonucleotide specifically hybridizes to the target region under conventional high stringency conditions. The skilled artisan can readily design and test oligonucleotide probes and primers suitable for detecting polymorphisms in the TNFRSF1A gene using the polymorphism information provided herein in conjunction with the known sequence information for the TNFRSF1A gene and routine techniques.

A nucleic acid molecule such as an oligonucleotide or polynucleotide is said to be a "perfect" or "complete" complement of another nucleic acid molecule if every nucleotide of one of the molecules is complementary to the nucleotide at the corresponding position of the other molecule. A nucleic acid molecule is "substantially complementary" to another molecule if it hybridizes to that molecule with sufficient stability to remain in a duplex form under conventional low-stringency conditions.

Conventional hybridization conditions are described, for example, by Sambrook J. et al., in Molecular Cloning, A Laboratory Manual, 2<sup>nd</sup> Edition, Cold Spring Harbor Press, Cold Spring Harbor, NY (1989) and by Haymes, B.D. et al. in Nucleic Acid Hybridization, A Practical Approach, IRL Press, Washington, D.C. (1985). While perfectly complementary oligonucleotides are preferred for detecting polymorphisms, departures from complete complementarity are contemplated where such departures do not prevent the molecule from specifically hybridizing to the target region. For example, an oligonucleotide primer may have a non-complementary fragment at its 5' end, with the remainder of the primer being complementary to the target region. Alternatively, non-complementary nucleotides may be interspersed into the probe or primer as long as the resulting probe or primer is still capable of specifically hybridizing to the target region.

Preferred haplotyping or genotyping oligonucleotides of the invention are allele-specific oligonucleotides. As used herein, the term allele-specific oligonucleotide (ASO) means an oligonucleotide that is able, under sufficiently stringent conditions, to hybridize specifically to one allele of a gene, or other locus, at a target region containing a polymorphic site while not hybridizing to the corresponding region in another allele(s). As understood by the skilled artisan, allele-specificity will depend upon a variety of readily optimized stringency conditions, including salt and formamide concentrations, as well as temperatures for both the hybridization and washing steps. Examples of hybridization and washing conditions typically used for ASO probes are found in Kogan et al., "Genetic Prediction of Hemophilia A" in PCR Protocols, A Guide to Methods and Applications, Academic Press, 1990 and Ruaño et al., 87 *Proc. Natl. Acad. Sci. USA* 6296-6300, 1990. Typically, an ASO will be perfectly complementary to one allele while containing a single mismatch for another allele.

Allele-specific oligonucleotides of the invention include ASO probes and ASO primers. ASO probes which usually provide good discrimination between different alleles are those in which a central position of the oligonucleotide probe aligns with the polymorphic site in the target region (e.g., approximately the 7<sup>th</sup> or 8<sup>th</sup> position in a 15mer, the 8<sup>th</sup> or 9<sup>th</sup> position in a 16mer, and the 10<sup>th</sup> or 11<sup>th</sup> position in a 20mer). An ASO primer of the invention has a 3' terminal nucleotide, or preferably a 3'

penultimate nucleotide, that is complementary to only one nucleotide of a particular SNP, thereby acting as a primer for polymerase-mediated extension only if the allele containing that nucleotide is present. ASO probes and primers hybridizing to either the coding or noncoding strand are contemplated by the invention. ASO probes and primers listed below use the appropriate nucleotide symbol (R= G or A, Y= T or C, M= A or C, K= G or T, S= G or C, and W= A or T; WIPO standard ST.25) at the position of the polymorphic site to represent that the ASO contains either of the two alternative allelic variants observed at that polymorphic site.

A preferred ASO probe for detecting TNFRSF1A gene polymorphisms comprises a nucleotide sequence, listed 5' to 3', selected from the group consisting of:

10 GCAGGGTKGGGGGAC (SEQ ID NO:4) and its complement,  
GAGTGGTSGGATTGG (SEQ ID NO:5) and its complement,  
AAGAAAGRATGTCCA (SEQ ID NO:6) and its complement,  
CTCTGCCYGCCTCCTC (SEQ ID NO:7) and its complement,  
GCCCGCTYCTCTGAC (SEQ ID NO:8) and its complement,  
15 CCCCGCARAGAGGTG (SEQ ID NO:9) and its complement, and  
GGGGCGGGRGCCTGGG (SEQ ID NO:10) and its complement.

A preferred ASO primer for detecting TNFRSF1A gene polymorphisms comprises a nucleotide sequence, listed 5' to 3', selected from the group consisting of:

20 AGTGGGGCAGGGTKG (SEQ ID NO:11); GGCCAGGTCCCCMA (SEQ ID NO:12);  
GGTTGGGAGTGGTSG (SEQ ID NO:13); AACCCACCAATCCSA (SEQ ID NO:14);  
TTTGTAAGAAAGRA (SEQ ID NO:15); GATTGTTGGACATYC (SEQ ID NO:16);  
GCCCCCTCTGCCYG (SEQ ID NO:17); TGGTCAGAGGAGCRG (SEQ ID NO:18);  
25 CCCTCTGCCCGCTYC (SEQ ID NO:19); GTGTTGGTCAGAGRA (SEQ ID NO:20);  
GCGGCTCCCCGCARA (SEQ ID NO:21); TGGTGCCACCTCTYT (SEQ ID NO:22);  
GGATGCGGGGGCGGRG (SEQ ID NO:23); and GGCACCCCAGGCYC (SEQ ID NO:24).

Other oligonucleotides of the invention hybridize to a target region located one to several nucleotides downstream of one of the novel polymorphic sites identified herein. Such oligonucleotides are useful in polymerase-mediated primer extension methods for detecting one of the novel polymorphisms described herein and therefore such oligonucleotides are referred to herein as "primer-extension oligonucleotides". In a preferred embodiment, the 3'-terminus of a primer-extension oligonucleotide is a deoxynucleotide complementary to the nucleotide located immediately adjacent to the polymorphic site.

A particularly preferred oligonucleotide primer for detecting TNFRSF1A gene polymorphisms by primer extension terminates in a nucleotide sequence, listed 5' to 3', selected from the group consisting of:

40 GGGGCAGGGT (SEQ ID NO:25); CAGGTCCCC (SEQ ID NO:26);  
TGGGAGTGGT (SEQ ID NO:27); CCACCAATCC (SEQ ID NO:28);  
GTAAAGAAAG (SEQ ID NO:29); TGTTGGACAT (SEQ ID NO:30);  
45 CCCCTCTGCC (SEQ ID NO:31); TCAGAGGAGC (SEQ ID NO:32);  
TCTGCCCGCT (SEQ ID NO:33); TTGGTCAGAG (SEQ ID NO:34);  
GCTCCCCGCA (SEQ ID NO:35); TGCCACCTCT (SEQ ID NO:36);

TGCGGGGCGG (SEQ ID NO:37) ; and AACCCCAGGC (SEQ ID NO:38) .

In some embodiments, a composition contains two or more differently labeled TNFRSF1A oligonucleotides for simultaneously probing the identity of nucleotides or nucleotide pairs at two or 5 more polymorphic sites. It is also contemplated that primer compositions may contain two or more sets of allele-specific primer pairs to allow simultaneous targeting and amplification of two or more regions containing a polymorphic site.

TNFRSF1A oligonucleotides of the invention may also be immobilized on or synthesized on a solid surface such as a microchip, bead, or glass slide (see, e.g., WO 98/20020 and WO 98/20019).

10 Such immobilized oligonucleotides may be used in a variety of polymorphism detection assays, including but not limited to probe hybridization and polymerase extension assays. Immobilized TNFRSF1A oligonucleotides of the invention may comprise an ordered array of oligonucleotides designed to rapidly screen a DNA sample for polymorphisms in multiple genes at the same time.

In another embodiment, the invention provides a kit comprising at least two TNFRSF1A oligonucleotides packaged in separate containers. The kit may also contain other components such as hybridization buffer (where the oligonucleotides are to be used as a probe) packaged in a separate container. Alternatively, where the oligonucleotides are to be used to amplify a target region, the kit may contain, packaged in separate containers, a polymerase and a reaction buffer optimized for primer extension mediated by the polymerase, such as PCR.

20 The above described oligonucleotide compositions and kits are useful in methods for genotyping and/or haplotyping the TNFRSF1A gene in an individual. As used herein, the terms “TNFRSF1A genotype” and “TNFRSF1A haplotype” mean the genotype or haplotype contains the nucleotide pair or nucleotide, respectively, that is present at one or more of the novel polymorphic sites described herein and may optionally also include the nucleotide pair or nucleotide present at one or 25 more additional polymorphic sites in the TNFRSF1A gene. The additional polymorphic sites may be currently known polymorphic sites or sites that are subsequently discovered.

One embodiment of a genotyping method of the invention involves isolating from the individual a nucleic acid sample comprising the two copies of the TNFRSF1A gene, mRNA transcripts thereof or cDNA copies thereof, or a fragment of any of the foregoing, that are present in the individual, 30 and determining the identity of the nucleotide pair at one or more polymorphic sites selected from the group consisting of PS1, PS4, PS12, PS14, PS15, PS17 and PS18 in the two copies to assign a TNFRSF1A genotype to the individual. As will be readily understood by the skilled artisan, the two “copies” of a gene, mRNA or cDNA (or fragment of such TNFRSF1A molecules) in an individual may be the same allele or may be different alleles. In a preferred embodiment of the method for assigning a 35 TNFRSF1A genotype, the identity of the nucleotide pair at one or more of the polymorphic sites selected from the group consisting of PS2, PS3, PS5, PS6, PS7, PS8, PS9, PS10, PS11, PS13 and PS16 is also determined. In another embodiment, a genotyping method of the invention comprises

determining the identity of the nucleotide pair at each of PS1-PS18.

Typically, the nucleic acid sample is isolated from a biological sample taken from the individual, such as a blood sample or tissue sample. Suitable tissue samples include whole blood, semen, saliva, tears, urine, fecal material, sweat, buccal, skin and hair. The nucleic acid sample may be 5 comprised of genomic DNA, mRNA, or cDNA and, in the latter two cases, the biological sample must be obtained from a tissue in which the TNFRSF1A gene is expressed. Furthermore it will be understood by the skilled artisan that mRNA or cDNA preparations would not be used to detect polymorphisms located in introns or in 5' and 3' untranslated regions if not present in the mRNA or cDNA. If a TNFRSF1A gene fragment is isolated, it must contain the polymorphic site(s) to be 10 genotyped.

One embodiment of a haplotyping method of the invention comprises isolating from the individual a nucleic acid sample containing only one of the two copies of the TNFRSF1A gene, mRNA or cDNA, or a fragment of such TNFRSF1A molecules, that is present in the individual and determining in that copy the identity of the nucleotide at one or more polymorphic sites selected from the group consisting of PS1, PS4, PS12, PS14, PS15, PS17 and PS18 in that copy to assign a TNFRSF1A haplotype to the individual.

The nucleic acid used in the above haplotyping methods of the invention may be isolated using any method capable of separating the two copies of the TNFRSF1A gene or fragment such as one of the methods described above for preparing TNFRSF1A isogenes, with targeted *in vivo* cloning being the preferred approach. As will be readily appreciated by those skilled in the art, any individual clone will typically only provide haplotype information on one of the two TNFRSF1A gene copies present in an individual. If haplotype information is desired for the individual's other copy, additional TNFRSF1A clones will usually need to be examined. Typically, at least five clones should be examined to have more than a 90% probability of haplotyping both copies of the TNFRSF1A gene in an individual. In 25 some cases, however, once the haplotype for one TNFRSF1A allele is directly determined, the haplotype for the other allele may be inferred if the individual has a known genotype for the polymorphic sites of interest or if the haplotype frequency or haplotype pair frequency for the individual's population group is known. In some embodiments, the TNFRSF1A haplotype is assigned to the individual by also identifying the nucleotide at one or more polymorphic sites selected from the 30 group consisting of PS2, PS3, PS5, PS6, PS7, PS8, PS9, PS10, PS11, PS13 and PS16. In a particularly preferred embodiment, the nucleotide at each of PS1-PS18 is identified.

In another embodiment, the haplotyping method comprises determining whether an individual has one or more of the TNFRSF1A haplotypes shown in Table 5. This can be accomplished by identifying, for one or both copies of the individual's TNFRSF1A gene, the phased sequence of 35 nucleotides present at each of PS1-PS18. This identifying step does not necessarily require that each of PS1-PS18 be directly examined. Typically only a subset of PS1-PS18 will need to be directly examined to assign to an individual one or more of the haplotypes shown in Table 5. This is because at least one

polymorphic site in a gene is frequently in strong linkage disequilibrium with one or more other polymorphic sites in that gene (Drysdale, CM et al. 2000 *PNAS* 97:10483-10488; Rieder MJ et al. 1999 *Nature Genetics* 22:59-62). Two sites are said to be in linkage disequilibrium if the presence of a particular variant at one site enhances the predictability of another variant at the second site (Stephens, JC 1999, *Mol. Diag.* 4:309-317). Techniques for determining whether any two polymorphic sites are in linkage disequilibrium are well-known in the art (Weir B.S. 1996 *Genetic Data Analysis II*, Sinauer Associates, Inc. Publishers, Sunderland, MA).

In another embodiment of a haplotyping method of the invention, a TNFRSF1A haplotype pair is determined for an individual by identifying the phased sequence of nucleotides at one or more polymorphic sites selected from the group consisting of PS1, PS4, PS12, PS14, PS15, PS17 and PS18 in each copy of the TNFRSF1A gene that is present in the individual. In a particularly preferred embodiment, the haplotyping method comprises identifying the phased sequence of nucleotides at each of PS1-PS18 in each copy of the TNFRSF1A gene.

When haplotyping both copies of the gene, the identifying step is preferably performed with each copy of the gene being placed in separate containers. However, it is also envisioned that if the two copies are labeled with different tags, or are otherwise separately distinguishable or identifiable, it could be possible in some cases to perform the method in the same container. For example, if first and second copies of the gene are labeled with different first and second fluorescent dyes, respectively, and an allele-specific oligonucleotide labeled with yet a third different fluorescent dye is used to assay the polymorphic site(s), then detecting a combination of the first and third dyes would identify the polymorphism in the first gene copy while detecting a combination of the second and third dyes would identify the polymorphism in the second gene copy.

In both the genotyping and haplotyping methods, the identity of a nucleotide (or nucleotide pair) at a polymorphic site(s) may be determined by amplifying a target region(s) containing the polymorphic site(s) directly from one or both copies of the TNFRSF1A gene, or a fragment thereof, and the sequence of the amplified region(s) determined by conventional methods. It will be readily appreciated by the skilled artisan that only one nucleotide will be detected at a polymorphic site in individuals who are homozygous at that site, while two different nucleotides will be detected if the individual is heterozygous for that site. The polymorphism may be identified directly, known as positive-type identification, or by inference, referred to as negative-type identification. For example, where a SNP is known to be guanine and cytosine in a reference population, a site may be positively determined to be either guanine or cytosine for an individual homozygous at that site, or both guanine and cytosine, if the individual is heterozygous at that site. Alternatively, the site may be negatively determined to be not guanine (and thus cytosine/cytosine) or not cytosine (and thus guanine/guanine).

The target region(s) may be amplified using any oligonucleotide-directed amplification method, including but not limited to polymerase chain reaction (PCR) (U.S. Patent No. 4,965,188), ligase chain reaction (LCR) (Barany et al., *Proc. Natl. Acad. Sci. USA* 88:189-193, 1991; WO90/01069), and

10 15 20 25 30

oligonucleotide ligation assay (OLA) (Landegren et al., *Science* 241:1077-1080, 1988). Other known nucleic acid amplification procedures may be used to amplify the target region including transcription-based amplification systems (U.S. Patent No. 5,130,238; EP 329,822; U.S. Patent No. 5,169,766, WO89/06700) and isothermal methods (Walker et al., *Proc. Natl. Acad. Sci. USA* 89:392-396, 1992).

5 A polymorphism in the target region may also be assayed before or after amplification using one of several hybridization-based methods known in the art. Typically, allele-specific oligonucleotides are utilized in performing such methods. The allele-specific oligonucleotides may be used as differently labeled probe pairs, with one member of the pair showing a perfect match to one variant of a target sequence and the other member showing a perfect match to a different variant. In 10 some embodiments, more than one polymorphic site may be detected at once using a set of allele-specific oligonucleotides or oligonucleotide pairs. Preferably, the members of the set have melting temperatures within 5°C, and more preferably within 2°C, of each other when hybridizing to each of the polymorphic sites being detected.

Hybridization of an allele-specific oligonucleotide to a target polynucleotide may be performed with both entities in solution, or such hybridization may be performed when either the oligonucleotide or the target polynucleotide is covalently or noncovalently affixed to a solid support. Attachment may be mediated, for example, by antibody-antigen interactions, poly-L-Lys, streptavidin or avidin-biotin, salt bridges, hydrophobic interactions, chemical linkages, UV cross-linking baking, etc. Allele-specific oligonucleotides may be synthesized directly on the solid support or attached to the solid support subsequent to synthesis. Solid-supports suitable for use in detection methods of the invention include substrates made of silicon, glass, plastic, paper and the like, which may be formed, for example, into wells (as in 96-well plates), slides, sheets, membranes, fibers, chips, dishes, and beads. The solid support may be treated, coated or derivatized to facilitate the immobilization of the allele-specific oligonucleotide or target nucleic acid.

25 The genotype or haplotype for the TNFRSF1A gene of an individual may also be determined by hybridization of a nucleic acid sample containing one or both copies of the gene, mRNA, cDNA or fragment(s) thereof, to nucleic acid arrays and subarrays such as described in WO 95/11995. The arrays would contain a battery of allele-specific oligonucleotides representing each of the polymorphic sites to be included in the genotype or haplotype.

30 The identity of polymorphisms may also be determined using a mismatch detection technique, including but not limited to the RNase protection method using riboprobes (Winter et al., *Proc. Natl. Acad. Sci. USA* 82:7575, 1985; Meyers et al., *Science* 230:1242, 1985) and proteins which recognize nucleotide mismatches, such as the E. coli mutS protein (Modrich, P. *Ann. Rev. Genet.* 25:229-253, 1991). Alternatively, variant alleles can be identified by single strand conformation polymorphism 35 (SSCP) analysis (Orita et al., *Genomics* 5:874-879, 1989; Humphries et al., in *Molecular Diagnosis of Genetic Diseases*, R. Elles, ed., pp. 321-340, 1996) or denaturing gradient gel electrophoresis (DGGE) (Wartell et al., *Nucl. Acids Res.* 18:2699-2706, 1990; Sheffield et al., *Proc. Natl. Acad. Sci. USA*

86:232-236, 1989).

A polymerase-mediated primer extension method may also be used to identify the polymorphism(s). Several such methods have been described in the patent and scientific literature and include the "Genetic Bit Analysis" method (WO92/15712) and the ligase/polymerase mediated genetic bit analysis (U.S. Patent 5,679,524. Related methods are disclosed in WO91/02087, WO90/09455, 5 WO95/17676, U.S. Patent Nos. 5,302,509, and 5,945,283. Extended primers containing a polymorphism may be detected by mass spectrometry as described in U.S. Patent No. 5,605,798. Another primer extension method is allele-specific PCR (Ruaño et al., *Nucl. Acids Res.* 17:8392, 1989; Ruaño et al., *Nucl. Acids Res.* 19, 6877-6882, 1991; WO 93/22456; Turki et al., *J. Clin. Invest.* 10 195:1635-1641, 1995). In addition, multiple polymorphic sites may be investigated by simultaneously amplifying multiple regions of the nucleic acid using sets of allele-specific primers as described in Wallace et al. (WO89/10414).

In addition, the identity of the allele(s) present at any of the novel polymorphic sites described herein may be indirectly determined by haplotyping or genotyping another polymorphic site that is in linkage disequilibrium with the polymorphic site that is of interest. Polymorphic sites in linkage disequilibrium with the presently disclosed polymorphic sites may be located in regions of the gene or in other genomic regions not examined herein. Detection of the allele(s) present at a polymorphic site in linkage disequilibrium with the novel polymorphic sites described herein may be performed by, but is not limited to, any of the above-mentioned methods for detecting the identity of the allele at a polymorphic site.

In another aspect of the invention, an individual's TNFRSF1A haplotype pair is predicted from its TNFRSF1A genotype using information on haplotype pairs known to exist in a reference population. In its broadest embodiment, the haplotyping prediction method comprises identifying a TNFRSF1A genotype for the individual at two or more TNFRSF1A polymorphic sites described herein, accessing 25 data containing TNFRSF1A haplotype pairs identified in a reference population, and assigning a haplotype pair to the individual that is consistent with the genotype data. In one embodiment, the reference haplotype pairs include the TNFRSF1A haplotype pairs shown in Table 4. The TNFRSF1A haplotype pair can be assigned by comparing the individual's genotype with the genotypes corresponding to the haplotype pairs known to exist in the general population or in a specific population 30 group, and determining which haplotype pair is consistent with the genotype of the individual. In some embodiments, comparison of the genotype of the individual to the haplotype pairs identified in a reference population and determination of which haplotype pair is consistent with the genotype of the individual may be performed by visual inspection (for example, by consulting Table 4). When the 35 genotype of the individual is consistent with more than one haplotype pair, frequency data (such as that presented in Table 7) may be used to determine which of these haplotype pairs is most likely to be present in the individual. This determination may also be performed in some embodiments by visual inspection upon consulting Table 7. If a particular TNFRSF1A haplotype pair consistent with the

genotype of the individual is more frequent in the reference population than others consistent with the genotype, then that haplotype pair with the highest frequency is the most likely to be present in the individual. In other embodiments, the comparison may be made by a computer-implemented algorithm with the genotype of the individual and the reference haplotype data stored in computer-readable formats. For example, as described in PCT/US01/12831, filed April 18, 2001, one computer-implemented algorithm to perform this comparison entails enumerating all possible haplotype pairs which are consistent with the genotype, accessing data containing TNFRSF1A haplotype pairs frequency data determined in a reference population to determine a probability that the individual has a possible haplotype pair, and analyzing the determined probabilities to assign a haplotype pair to the individual.

Generally, the reference population should be composed of randomly-selected individuals representing the major ethnogeographic groups of the world. A preferred reference population for use in the methods of the present invention comprises an approximately equal number of individuals from Caucasian, African-descent, Asian and Hispanic-Latino population groups with the minimum number of each group being chosen based on how rare a haplotype one wants to be guaranteed to see. For example, if one wants to have a q% chance of not missing a haplotype that exists in the population at a p% frequency of occurring in the reference population, the number of individuals (n) who must be sampled is given by  $2n = \log(1-q)/\log(1-p)$  where p and q are expressed as fractions. A preferred reference population allows the detection of any haplotype whose frequency is at least 10% with about 99% certainty and comprises about 20 unrelated individuals from each of the four population groups named above. A particularly preferred reference population includes a 3-generation family representing one or more of the four population groups to serve as controls for checking quality of haplotyping procedures.

In a preferred embodiment, the haplotype frequency data for each ethnogeographic group is examined to determine whether it is consistent with Hardy-Weinberg equilibrium. Hardy-Weinberg equilibrium (D.L. Hartl et al., Principles of Population Genomics, Sinauer Associates (Sunderland, MA), 3<sup>rd</sup> Ed., 1997) postulates that the frequency of finding the haplotype pair  $H_1 / H_2$  is equal to  $p_{H-W}(H_1 / H_2) = 2p(H_1)p(H_2)$  if  $H_1 \neq H_2$  and  $p_{H-W}(H_1 / H_2) = p(H_1)p(H_2)$  if  $H_1 = H_2$ . A statistically significant difference between the observed and expected haplotype frequencies could be due to one or more factors including significant inbreeding in the population group, strong selective pressure on the gene, sampling bias, and/or errors in the genotyping process. If large deviations from Hardy-Weinberg equilibrium are observed in an ethnogeographic group, the number of individuals in that group can be increased to see if the deviation is due to a sampling bias. If a larger sample size does not reduce the difference between observed and expected haplotype pair frequencies, then one may wish to consider haplotyping the individual using a direct haplotyping method such as, for example, CLASPER System™ technology (U.S. Patent No. 5,866,404), single molecule dilution, or allele-specific

long-range PCR (Michalotos-Beloin et al., *Nucleic Acids Res.* 24:4841-4843, 1996).

In one embodiment of this method for predicting a TNFRSF1A haplotype pair for an individual, the assigning step involves performing the following analysis. First, each of the possible haplotype pairs is compared to the haplotype pairs in the reference population. Generally, only one of the 5 haplotype pairs in the reference population matches a possible haplotype pair and that pair is assigned to the individual. Occasionally, only one haplotype represented in the reference haplotype pairs is consistent with a possible haplotype pair for an individual, and in such cases the individual is assigned a haplotype pair containing this known haplotype and a new haplotype derived by subtracting the known haplotype from the possible haplotype pair. Alternatively, the haplotype pair in an 10 individual may be predicted from the individual's genotype for that gene using reported methods (e.g., Clark et al. 1990 *Mol Bio Evol* 7:111-22; copending PCT/US01/12831 filed April 18, 2001 ) or through a commercial haplotyping service such as offered by Genaissance Pharmaceuticals, Inc. (New Haven, CT). In rare cases, either no haplotypes in the reference population are consistent with the possible 15 haplotype pairs, or alternatively, multiple reference haplotype pairs are consistent with the possible haplotype pairs. In such cases, the individual is preferably haplotyped using a direct molecular haplotyping method such as, for example, CLASPER System™ technology (U.S. Patent No. 5,866,404), SMD, or allele-specific long-range PCR (Michalotos-Beloin et al., *supra*).

The invention also provides a method for determining the frequency of a TNFRSF1A genotype, haplotype, or haplotype pair in a population. The method comprises, for each member of the population, determining the genotype or the haplotype pair for the novel TNFRSF1A polymorphic sites described herein, and calculating the frequency any particular genotype, haplotype, or haplotype pair is found in the population. The population may be e.g., a reference population, a family population, a same gender population, a population group, or a trait population (e.g., a group of individuals exhibiting a trait of interest such as a medical condition or response to a therapeutic treatment).

25 In another aspect of the invention, frequency data for TNFRSF1A genotypes, haplotypes, and/or haplotype pairs are determined in a reference population and used in a method for identifying an association between a trait and a TNFRSF1A genotype, haplotype, or haplotype pair. The trait may be any detectable phenotype, including but not limited to susceptibility to a disease or response to a treatment. In one embodiment, the method involves obtaining data on the frequency of the genotype(s), 30 haplotype(s), or haplotype pair(s) of interest in a reference population as well as in a population exhibiting the trait. Frequency data for one or both of the reference and trait populations may be obtained by genotyping or haplotyping each individual in the populations using one or more of the methods described above. The haplotypes for the trait population may be determined directly or, alternatively, by a predictive genotype to haplotype approach as described above. In another 35 embodiment, the frequency data for the reference and/or trait populations is obtained by accessing previously determined frequency data, which may be in written or electronic form. For example, the frequency data may be present in a database that is accessible by a computer. Once the frequency data

is obtained, the frequencies of the genotype(s), haplotype(s), or haplotype pair(s) of interest in the reference and trait populations are compared. In a preferred embodiment, the frequencies of all genotypes, haplotypes, and/or haplotype pairs observed in the populations are compared. If a particular TNFRSF1A genotype, haplotype, or haplotype pair is more frequent in the trait population than in the reference population at a statistically significant amount, then the trait is predicted to be associated with that TNFRSF1A genotype, haplotype or haplotype pair. Preferably, the TNFRSF1A genotype, haplotype, or haplotype pair being compared in the trait and reference populations is selected from the full-genotypes and full-haplotypes shown in Tables 4 and 5, or from sub-genotypes and sub-haplotypes derived from these genotypes and haplotypes. Sub-genotypes useful in the invention preferably do not include sub-genotypes solely for any one of PS2, PS3, PS5, PS6, PS7, PS8, PS9, PS10, PS11, PS13 and PS16 or for any combination thereof.

In a preferred embodiment of the method, the trait of interest is a clinical response exhibited by a patient to some therapeutic treatment, for example, response to a drug targeting TNFRSF1A or response to a therapeutic treatment for a medical condition. As used herein, "medical condition" includes but is not limited to any condition or disease manifested as one or more physical and/or psychological symptoms for which treatment is desirable, and includes previously and newly identified diseases and other disorders. As used herein the term "clinical response" means any or all of the following: a quantitative measure of the response, no response, and/or adverse response (i.e., side effects).

In order to deduce a correlation between clinical response to a treatment and a TNFRSF1A genotype, haplotype, or haplotype pair, it is necessary to obtain data on the clinical responses exhibited by a population of individuals who received the treatment, hereinafter the "clinical population". This clinical data may be obtained by analyzing the results of a clinical trial that has already been run and/or the clinical data may be obtained by designing and carrying out one or more new clinical trials. As used herein, the term "clinical trial" means any research study designed to collect clinical data on responses to a particular treatment, and includes but is not limited to phase I, phase II and phase III clinical trials. Standard methods are used to define the patient population and to enroll subjects.

It is preferred that the individuals included in the clinical population have been graded for the existence of the medical condition of interest. This is important in cases where the symptom(s) being presented by the patients can be caused by more than one underlying condition, and where treatment of the underlying conditions are not the same. An example of this would be where patients experience breathing difficulties that are due to either asthma or respiratory infections. If both sets were treated with an asthma medication, there would be a spurious group of apparent non-responders that did not actually have asthma. These people would affect the ability to detect any correlation between haplotype and treatment outcome. This grading of potential patients could employ a standard physical exam or one or more lab tests. Alternatively, grading of patients could use haplotyping for situations where there is a strong correlation between haplotype pair and disease susceptibility or severity.

The therapeutic treatment of interest is administered to each individual in the trial population and each individual's response to the treatment is measured using one or more predetermined criteria. It is contemplated that in many cases, the trial population will exhibit a range of responses and that the investigator will choose the number of responder groups (e.g., low, medium, high) made up by the 5 various responses. In addition, the TNFRSF1A gene for each individual in the trial population is genotyped and/or haplotyped, which may be done before or after administering the treatment.

After both the clinical and polymorphism data have been obtained, correlations between individual response and TNFRSF1A genotype or haplotype content are created. Correlations may be produced in several ways. In one method, individuals are grouped by their TNFRSF1A genotype or 10 haplotype (or haplotype pair) (also referred to as a polymorphism group), and then the averages and standard deviations of clinical responses exhibited by the members of each polymorphism group are calculated.

These results are then analyzed to determine if any observed variation in clinical response between polymorphism groups is statistically significant. Statistical analysis methods which may be used are described in L.D. Fisher and G. vanBelle, "Biostatistics: A Methodology for the Health Sciences", Wiley-Interscience (New York) 1993. This analysis may also include a regression calculation of which polymorphic sites in the TNFRSF1A gene give the most significant contribution to the differences in phenotype. One regression model useful in the invention is described in WO 01/01218, entitled "Methods for Obtaining and Using Haplotype Data".

A second method for finding correlations between TNFRSF1A haplotype content and clinical responses uses predictive models based on error-minimizing optimization algorithms. One of many possible optimization algorithms is a genetic algorithm (R. Judson, "Genetic Algorithms and Their Uses in Chemistry" in *Reviews in Computational Chemistry*, Vol. 10, pp. 1-73, K. B. Lipkowitz and D. B. Boyd, eds. (VCH Publishers, New York, 1997). Simulated annealing (Press et al., "Numerical Recipes 25 in C: The Art of Scientific Computing", Cambridge University Press (Cambridge) 1992, Ch. 10), neural networks (E. Rich and K. Knight, "Artificial Intelligence", 2<sup>nd</sup> Edition (McGraw-Hill, New York, 1991, Ch. 18), standard gradient descent methods (Press et al., *supra*, Ch. 10), or other global or local optimization approaches (see discussion in Judson, *supra*) could also be used. Preferably, the correlation is found using a genetic algorithm approach as described in WO 01/01218.

30 Correlations may also be analyzed using analysis of variation (ANOVA) techniques to determine how much of the variation in the clinical data is explained by different subsets of the polymorphic sites in the TNFRSF1A gene. As described in WO 01/01218, ANOVA is used to test hypotheses about whether a response variable is caused by or correlated with one or more traits or variables that can be measured (Fisher and vanBelle, *supra*, Ch. 10).

35 From the analyses described above, a mathematical model may be readily constructed by the skilled artisan that predicts clinical response as a function of TNFRSF1A genotype or haplotype content. Preferably, the model is validated in one or more follow-up clinical trials designed to test the

15  
20  
25  
30

model.

The identification of an association between a clinical response and a genotype or haplotype (or haplotype pair) for the TNFRSF1A gene may be the basis for designing a diagnostic method to determine those individuals who will or will not respond to the treatment, or alternatively, will respond 5 at a lower level and thus may require more treatment, i.e., a greater dose of a drug. The diagnostic method may take one of several forms: for example, a direct DNA test (i.e., genotyping or haplotyping one or more of the polymorphic sites in the TNFRSF1A gene), a serological test, or a physical exam measurement. The only requirement is that there be a good correlation between the diagnostic test results and the underlying TNFRSF1A genotype or haplotype that is in turn correlated with the clinical 10 response. In a preferred embodiment, this diagnostic method uses the predictive haplotyping method described above.

In another embodiment, the invention provides an isolated polynucleotide comprising a polymorphic variant of the TNFRSF1A gene or a fragment of the gene which contains at least one of the novel polymorphic sites described herein. The nucleotide sequence of a variant TNFRSF1A gene is identical to the reference genomic sequence for those portions of the gene examined, as described in the Examples below, except that it comprises a different nucleotide at one or more of the novel polymorphic sites PS1, PS4, PS12, PS14, PS15, PS17 and PS18, and may also comprise one or more additional polymorphisms selected from the group consisting of guanine at PS2, guanine at PS3, guanine at PS5, adenine at PS6, thymine at PS7, adenine at PS8, cytosine at PS9, thymine at PS10, cytosine at PS11, guanine at PS13 and cytosine at PS16. Similarly, the nucleotide sequence of a variant fragment of the TNFRSF1A gene is identical to the corresponding portion of the reference sequence except for having a different nucleotide at one or more of the novel polymorphic sites described herein. Thus, the invention specifically does not include polynucleotides comprising a nucleotide sequence identical to the reference sequence of the TNFRSF1A gene (or other reported TNFRSF1A sequences) 25 or to portions of the reference sequence (or other reported TNFRSF1A sequences), except for the haplotyping and genotyping oligonucleotides described above.

The location of a polymorphism in a variant TNFRSF1A gene or fragment is preferably identified by aligning its sequence against SEQ ID NO:1. The polymorphism is selected from the group consisting of thymine at PS1, guanine at PS4, adenine at PS12, thymine at PS14, thymine at PS15, 30 adenine at PS17 and adenine at PS18. In a preferred embodiment, the polymorphic variant comprises a naturally-occurring isogene of the TNFRSF1A gene which is defined by any one of haplotypes 1-27 shown in Table 5 below.

Polymorphic variants of the invention may be prepared by isolating a clone containing the TNFRSF1A gene from a human genomic library. The clone may be sequenced to determine the 35 identity of the nucleotides at the novel polymorphic sites described herein. Any particular variant or fragment thereof, that is claimed herein could be prepared from this clone by performing *in vitro* mutagenesis using procedures well-known in the art. Any particular TNFRSF1A variant or fragment

9  
15  
20  
25  
30  
35

thereof may also be prepared using synthetic or semi-synthetic methods known in the art.

TNFRSF1A isogenes, or fragments thereof, may be isolated using any method that allows separation of the two "copies" of the TNFRSF1A gene present in an individual, which, as readily understood by the skilled artisan, may be the same allele or different alleles. Separation methods include targeted *in vivo* cloning (TIVC) in yeast as described in WO 98/01573, U.S. Patent No. 5,866,404, and U.S. Patent No. 5,972,614. Another method, which is described in U.S. Patent No. 5,972,614, uses an allele specific oligonucleotide in combination with primer extension and exonuclease degradation to generate hemizygous DNA targets. Yet other methods are single molecule dilution (SMD) as described in Ruaño et al., *Proc. Natl. Acad. Sci.* 87:6296-6300, 1990; and allele specific PCR (Ruaño et al., 1989, *supra*; Ruaño et al., 1991, *supra*; Michalatos-Beloin et al., *supra*).

The invention also provides TNFRSF1A genome anthologies, which are collections of at least two TNFRSF1A isogenes found in a given population. The population may be any group of at least two individuals, including but not limited to a reference population, a population group, a family population, a clinical population, and a same gender population. A TNFRSF1A genome anthology may comprise individual TNFRSF1A isogenes stored in separate containers such as microtest tubes, separate wells of a microtitre plate and the like. Alternatively, two or more groups of the TNFRSF1A isogenes in the anthology may be stored in separate containers. Individual isogenes or groups of such isogenes in a genome anthology may be stored in any convenient and stable form, including but not limited to in buffered solutions, as DNA precipitates, freeze-dried preparations and the like. A preferred TNFRSF1A genome anthology of the invention comprises a set of isogenes defined by the haplotypes shown in Table 5 below. A TNFRSF1A genome anthology is useful in providing control nucleic acids for kits of the invention.

An isolated polynucleotide containing a polymorphic variant nucleotide sequence of the invention may be operably linked to one or more expression regulatory elements in a recombinant expression vector capable of being propagated and expressing the encoded TNFRSF1A protein in a prokaryotic or a eukaryotic host cell. Examples of expression regulatory elements which may be used include, but are not limited to, the lac system, operator and promoter regions of phage lambda, yeast promoters, and promoters derived from vaccinia virus, adenovirus, retroviruses, or SV40. Other regulatory elements include, but are not limited to, appropriate leader sequences, termination codons, polyadenylation signals, and other sequences required for the appropriate transcription and subsequent translation of the nucleic acid sequence in a given host cell. Of course, the correct combinations of expression regulatory elements will depend on the host system used. In addition, it is understood that the expression vector contains any additional elements necessary for its transfer to and subsequent replication in the host cell. Examples of such elements include, but are not limited to, origins of replication and selectable markers. Such expression vectors are commercially available or are readily constructed using methods known to those in the art (e.g., F. Ausubel et al., 1987, in "Current Protocols in Molecular Biology", John Wiley and Sons, New York, New York). Host cells which may be used to

express the variant TNFRSF1A sequences of the invention include, but are not limited to, eukaryotic and mammalian cells, such as animal, plant, insect and yeast cells, and prokaryotic cells, such as E. coli, or algal cells as known in the art. The recombinant expression vector may be introduced into the host cell using any method known to those in the art including, but not limited to, microinjection,  
5 electroporation, particle bombardment, transduction, and transfection using DEAE-dextran, lipofection, or calcium phosphate (see e.g., Sambrook et al. (1989) in "Molecular Cloning. A Laboratory Manual", Cold Spring Harbor Press, Plainview, New York). In a preferred aspect, eukaryotic expression vectors that function in eukaryotic cells, and preferably mammalian cells, are used. Non-limiting examples of such vectors include vaccinia virus vectors, adenovirus vectors, herpes virus vectors, and baculovirus  
10 transfer vectors. Preferred eukaryotic cell lines include COS cells, CHO cells, HeLa cells, NIH/3T3 cells, and embryonic stem cells (Thomson, J. A. et al., 1998 *Science* 282:1145-1147). Particularly preferred host cells are mammalian cells.

As will be readily recognized by the skilled artisan, expression of polymorphic variants of the TNFRSF1A gene will produce TNFRSF1A mRNAs varying from each other at any polymorphic site retained in the spliced and processed mRNA molecules. These mRNAs can be used for the preparation of a TNFRSF1A cDNA comprising a nucleotide sequence which is a polymorphic variant of the TNFRSF1A reference coding sequence shown in Figure 2. Thus, the invention also provides TNFRSF1A mRNAs and corresponding cDNAs which comprise a nucleotide sequence that is identical to SEQ ID NO:2 (Fig. 2), or its corresponding RNA sequence, for those regions of SEQ ID NO:2 that correspond to the examined portions of the TNFRSF1A gene (as described in the Examples below), except for having adenine at a position corresponding to nucleotide 935, and may also comprise one or more additional polymorphisms selected from the group consisting of thymine at a position corresponding to nucleotide 224, adenine at a position corresponding to nucleotide 362 and cytosine at a position corresponding to nucleotide 403. A particularly preferred polymorphic cDNA variant  
25 comprises the coding sequence of a TNFRSF1A isogene defined by any one of haplotypes 8, 9, 14, 17, and 19. Fragments of these variant mRNAs and cDNAs are included in the scope of the invention, provided they contain the novel polymorphism described herein. The invention specifically excludes polynucleotides identical to previously identified and characterized TNFRSF1A mRNAs, cDNAs or fragments thereof. Polynucleotides comprising a variant TNFRSF1A RNA or DNA sequence may be  
30 isolated from a biological sample using well-known molecular biological procedures or may be chemically synthesized.

As used herein, a polymorphic variant of a TNFRSF1A gene, mRNA or cDNA fragment comprises at least one novel polymorphism identified herein and has a length of at least 10 nucleotides and may range up to the full length of the gene. Preferably, such fragments are between 100 and 3000  
35 nucleotides in length, and more preferably between 200 and 2000 nucleotides in length, and most preferably between 500 and 1000 nucleotides in length.

In describing the TNFRSF1A polymorphic sites identified herein, reference is made to the

sense strand of the gene for convenience. However, as recognized by the skilled artisan, nucleic acid molecules containing the TNFRSF1A gene or cDNA may be complementary double stranded molecules and thus reference to a particular site on the sense strand refers as well to the corresponding site on the complementary antisense strand. Thus, reference may be made to the same polymorphic site 5 on either strand and an oligonucleotide may be designed to hybridize specifically to either strand at a target region containing the polymorphic site. Thus, the invention also includes single-stranded polynucleotides which are complementary to the sense strand of the TNFRSF1A genomic, mRNA and cDNA variants described herein.

Polynucleotides comprising a polymorphic gene variant or fragment of the invention may be 10 useful for therapeutic purposes. For example, where a patient could benefit from expression, or increased expression, of a particular TNFRSF1A protein isoform, an expression vector encoding the isoform may be administered to the patient. The patient may be one who lacks the TNFRSF1A isogene encoding that isoform or may already have at least one copy of that isogene.

In other situations, it may be desirable to decrease or block expression of a particular TNFRSF1A isogene. Expression of a TNFRSF1A isogene may be turned off by transforming a targeted organ, tissue or cell population with an expression vector that expresses high levels of untranslatable mRNA or antisense RNA for the isogene or fragment thereof. Alternatively, oligonucleotides directed against the regulatory regions (e.g., promoter, introns, enhancers, 3' untranslated region) of the isogene may block transcription. Oligonucleotides targeting the transcription initiation site, e.g., between positions -10 and +10 from the start site are preferred. Similarly, inhibition of transcription can be achieved using oligonucleotides that base-pair with region(s) of the isogene DNA to form triplex DNA (see e.g., Gee et al. in Huber, B.E. and B.I. Carr, Molecular and Immunologic Approaches, Futura Publishing Co., Mt. Kisco, N.Y., 1994). Antisense oligonucleotides may also be designed to block translation of TNFRSF1A mRNA transcribed from a 25 particular isogene. It is also contemplated that ribozymes may be designed that can catalyze the specific cleavage of TNFRSF1A mRNA transcribed from a particular isogene.

The untranslated mRNA, antisense RNA or antisense oligonucleotides may be delivered to a target cell or tissue by expression from a vector introduced into the cell or tissue *in vivo* or *ex vivo*. Alternatively, such molecules may be formulated as a pharmaceutical composition for administration to 30 the patient. Oligoribonucleotides and/or oligodeoxynucleotides intended for use as antisense oligonucleotides may be modified to increase stability and half-life. Possible modifications include, but are not limited to phosphorothioate or 2' O-methyl linkages, and the inclusion of nontraditional bases such as inosine and queosine, as well as acetyl-, methyl-, thio-, and similarly modified forms of adenine, cytosine, guanine, thymine, and uracil which are not as easily recognized by endogenous 35 nucleases.

The invention also provides an isolated polypeptide comprising a polymorphic variant of (a) the reference TNFRSF1A amino acid sequence shown in Figure 3 or (b) a fragment of this reference

sequence. The location of a variant amino acid in a TNFRSF1A polypeptide or fragment of the invention is identified by aligning its sequence against SEQ ID NO:3 (Fig. 3). A TNFRSF1A protein variant of the invention comprises an amino acid sequence identical to SEQ ID NO:3 for those regions of SEQ ID NO:3 that are encoded by examined portions of the TNFRSF1A gene (as described in the 5 Examples below), except for having lysine at a position corresponding to amino acid position 312, and may also comprise one or more additional variant amino acids selected from the group consisting of leucine at a position corresponding to amino acid position 75, glutamine at a position corresponding to amino acid position 121 and histidine at a position corresponding to amino acid position 135. Thus, a TNFRSF1A fragment of the invention, also referred to herein as a TNFRSF1A peptide variant, is any 10 fragment of a TNFRSF1A protein variant that contains lysine at a position corresponding to amino acid position 312. The invention specifically excludes amino acid sequences identical to those previously identified for TNFRSF1A, including SEQ ID NO:3, and previously described fragments thereof.

TNFRSF1A protein variants included within the invention comprise all amino acid sequences based on SEQ ID NO:3 and having the combination of amino acid variations described in Table 2 below. In preferred embodiments, a TNFRSF1A protein variant of the invention is encoded by an isogene defined by one of the observed haplotypes, 8, 9, 14, 17, and 19, shown in Table 5.

Table 2. Novel Polymorphic Variants of TNFRSF1A

Polymorphic Amino Acid Position and Identities

Variant	75	121	135	312	
Number	75	121	135	312	
1	P	R	Y	K	
3	P	R	H	K	
4	P	Q	Y	R	
5	P	Q	Y	K	
25	6	P	Q	H	R
7	P	Q	H	K	
8	L	R	Y	R	
9	L	R	Y	K	
10	L	R	H	R	
30	11	L	R	H	K
12	L	Q	Y	R	
13	L	Q	Y	K	
14	L	Q	H	R	
35	15	L	Q	H	K

A TNFRSF1A peptide variant of the invention is at least 6 amino acids in length and is preferably any number between 6 and 30 amino acids long, more preferably between 10 and 25, and most preferably between 15 and 20 amino acids long. Such TNFRSF1A peptide variants may be useful as antigens to generate antibodies specific for one of the above TNFRSF1A isoforms. In addition, the 40 TNFRSF1A peptide variants may be useful in drug screening assays.

A TNFRSF1A variant protein or peptide of the invention may be prepared by chemical synthesis or by expressing an appropriate variant TNFRSF1A genomic or cDNA sequence described above. Alternatively, the TNFRSF1A protein variant may be isolated from a biological sample of an

individual having a TNFRSF1A isogene which encodes the variant protein. Where the sample contains two different TNFRSF1A isoforms (i.e., the individual has different TNFRSF1A isogenes), a particular TNFRSF1A isoform of the invention can be isolated by immunoaffinity chromatography using an antibody which specifically binds to that particular TNFRSF1A isoform but does not bind to the other

5 TNFRSF1A isoform.

The expressed or isolated TNFRSF1A protein or peptide may be detected by methods known in the art, including Coomassie blue staining, silver staining, and Western blot analysis using antibodies specific for the isoform of the TNFRSF1A protein or peptide as discussed further below. TNFRSF1A variant proteins and peptides can be purified by standard protein purification procedures known in the  
10 art, including differential precipitation, molecular sieve chromatography, ion-exchange chromatography, isoelectric focusing, gel electrophoresis, affinity and immunoaffinity chromatography and the like. (Ausubel et. al., 1987, In Current Protocols in Molecular Biology John Wiley and Sons, New York, New York). In the case of immunoaffinity chromatography, antibodies specific for a particular polymorphic variant may be used.

A polymorphic variant TNFRSF1A gene of the invention may also be fused in frame with a heterologous sequence to encode a chimeric TNFRSF1A protein. The non-TNFRSF1A portion of the chimeric protein may be recognized by a commercially available antibody. In addition, the chimeric protein may also be engineered to contain a cleavage site located between the TNFRSF1A and non-TNFRSF1A portions so that the TNFRSF1A protein may be cleaved and purified away from the non-TNFRSF1A portion.

An additional embodiment of the invention relates to using a novel TNFRSF1A protein isoform, or a fragment thereof, in any of a variety of drug screening assays. Such screening assays may be performed to identify agents that bind specifically to all known TNFRSF1A protein isoforms or to only a subset of one or more of these isoforms. The agents may be from chemical compound libraries,  
25 peptide libraries and the like. The TNFRSF1A protein or peptide variant may be free in solution or affixed to a solid support. In one embodiment, high throughput screening of compounds for binding to a TNFRSF1A variant may be accomplished using the method described in PCT application WO84/03565, in which large numbers of test compounds are synthesized on a solid substrate, such as plastic pins or some other surface, contacted with the TNFRSF1A protein(s) of interest and then  
30 washed. Bound TNFRSF1A protein(s) are then detected using methods well-known in the art.

In another embodiment, a novel TNFRSF1A protein isoform may be used in assays to measure the binding affinities of one or more candidate drugs targeting the TNFRSF1A protein.

In yet another embodiment, when a particular TNFRSF1A haplotype or group of TNFRSF1A haplotypes encodes a TNFRSF1A protein variant with an amino acid sequence distinct from that of  
35 TNFRSF1A protein isoforms encoded by other TNFRSF1A haplotypes, then detection of that particular TNFRSF1A haplotype or group of TNFRSF1A haplotypes may be accomplished by detecting expression of the encoded TNFRSF1A protein variant using any of the methods described herein or

PCT/US98/05459

otherwise commonly known to the skilled artisan.

In another embodiment, the invention provides antibodies specific for and immunoreactive with one or more of the novel TNFRSF1A variant proteins described herein. The antibodies may be either monoclonal or polyclonal in origin. The TNFRSF1A protein or peptide variant used to generate the 5 antibodies may be from natural or recombinant sources or produced by chemical synthesis using synthesis techniques known in the art. If the TNFRSF1A protein variant is of insufficient size to be antigenic, it may be conjugated, complexed, or otherwise covalently linked to a carrier molecule to enhance the antigenicity of the peptide. Examples of carrier molecules, include, but are not limited to, albumins (e.g., human, bovine, fish, ovine), and keyhole limpet hemocyanin (Basic and Clinical 10 Immunology, 1991, Eds. D.P. Stites, and A.I. Terr, Appleton and Lange, Norwalk Connecticut, San Mateo, California).

In one embodiment, an antibody specifically immunoreactive with one of the novel protein isoforms described herein is administered to an individual to neutralize activity of the TNFRSF1A isoform expressed by that individual. The antibody may be formulated as a pharmaceutical composition which includes a pharmaceutically acceptable carrier.

Antibodies specific for and immunoreactive with one of the novel protein isoforms described herein may be used to immunoprecipitate the TNFRSF1A protein variant from solution as well as react with TNFRSF1A protein isoforms on Western or immunoblots of polyacrylamide gels on membrane supports or substrates. In another preferred embodiment, the antibodies will detect TNFRSF1A protein isoforms in paraffin or frozen tissue sections, or in cells which have been fixed or unfixed and prepared on slides, coverslips, or the like, for use in immunocytochemical, immunohistochemical, and immunofluorescence techniques.

In another embodiment, an antibody specifically immunoreactive with one of the novel TNFRSF1A protein variants described herein is used in immunoassays to detect this variant in 25 biological samples. In this method, an antibody of the present invention is contacted with a biological sample and the formation of a complex between the TNFRSF1A protein variant and the antibody is detected. As described, suitable immunoassays include radioimmunoassay, Western blot assay, immunofluorescent assay, enzyme linked immunoassay (ELISA), chemiluminescent assay, immunohistochemical assay, immunocytochemical assay, and the like (see, e.g., Principles and Practice 30 of Immunoassay, 1991, Eds. Christopher P. Price and David J. Neoman, Stockton Press, New York, New York; Current Protocols in Molecular Biology, 1987, Eds. Ausubel et al., John Wiley and Sons, New York, New York). Standard techniques known in the art for ELISA are described in Methods in Immunodiagnosis, 2nd Ed., Eds. Rose and Bigazzi, John Wiley and Sons, New York 1980; and Campbell et al., 1984, Methods in Immunology, W.A. Benjamin, Inc.). Such assays may be direct, 35 indirect, competitive, or noncompetitive as described in the art (see, e.g., Principles and Practice of Immunoassay, 1991, Eds. Christopher P. Price and David J. Neoman, Stockton Pres, NY, NY; and Oellrich, M., 1984, J. Clin. Chem. Clin. Biochem., 22:895-904). Proteins may be isolated from test

PCT/US98/03569  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24

specimens and biological samples by conventional methods, as described in Current Protocols in Molecular Biology, supra.

Exemplary antibody molecules for use in the detection and therapy methods of the present invention are intact immunoglobulin molecules, substantially intact immunoglobulin molecules, or 5 those portions of immunoglobulin molecules that contain the antigen binding site. Polyclonal or monoclonal antibodies may be produced by methods conventionally known in the art (e.g., Kohler and Milstein, 1975, *Nature*, 256:495-497; Campbell Monoclonal Antibody Technology, the Production and Characterization of Rodent and Human Hybridomas, 1985, In: *Laboratory Techniques in Biochemistry and Molecular Biology*, Eds. Burdon et al., Volume 13, Elsevier Science Publishers, Amsterdam). The 10 antibodies or antigen binding fragments thereof may also be produced by genetic engineering. The technology for expression of both heavy and light chain genes in *E. coli* is the subject of PCT patent applications, publication number WO 901443, WO 901443 and WO 9014424 and in Huse et al., 1989, *Science*, 246:1275-1281. The antibodies may also be humanized (e.g., Queen, C. et al. 1989 *Proc. Natl. Acad. Sci. USA* 86;10029).

Effect(s) of the polymorphisms identified herein on expression of TNFRSF1A may be investigated by preparing recombinant cells and/or nonhuman recombinant organisms, preferably recombinant animals, containing a polymorphic variant of the TNFRSF1A gene. As used herein, “expression” includes but is not limited to one or more of the following: transcription of the gene into precursor mRNA; splicing and other processing of the precursor mRNA to produce mature mRNA; mRNA stability; translation of the mature mRNA into TNFRSF1A protein (including codon usage and tRNA availability); and glycosylation and/or other modifications of the translation product, if required for proper expression and function.

To prepare a recombinant cell of the invention, the desired TNFRSF1A isogene may be introduced into the cell in a vector such that the isogene remains extrachromosomal. In such a situation, 25 the gene will be expressed by the cell from the extrachromosomal location. In a preferred embodiment, the TNFRSF1A isogene is introduced into a cell in such a way that it recombines with the endogenous TNFRSF1A gene present in the cell. Such recombination requires the occurrence of a double recombination event, thereby resulting in the desired TNFRSF1A gene polymorphism. Vectors for the introduction of genes both for recombination and for extrachromosomal maintenance are known in the 30 art, and any suitable vector or vector construct may be used in the invention. Methods such as electroporation, particle bombardment, calcium phosphate co-precipitation and viral transduction for introducing DNA into cells are known in the art; therefore, the choice of method may lie with the competence and preference of the skilled practitioner. Examples of cells into which the TNFRSF1A isogene may be introduced include, but are not limited to, continuous culture cells, such as COS, 35 NIH/3T3, and primary or culture cells of the relevant tissue type, i.e., they express the TNFRSF1A isogene. Such recombinant cells can be used to compare the biological activities of the different protein variants.

RECEIVED  
U.S. PATENT AND TRADEMARK OFFICE  
JULY 20 1998

Recombinant nonhuman organisms, i.e., transgenic animals, expressing a variant TNFRSF1A gene are prepared using standard procedures known in the art. Preferably, a construct comprising the variant gene is introduced into a nonhuman animal or an ancestor of the animal at an embryonic stage, i.e., the one-cell stage, or generally not later than about the eight-cell stage. Transgenic animals  
5 carrying the constructs of the invention can be made by several methods known to those having skill in the art. One method involves transfecting into the embryo a retrovirus constructed to contain one or more insulator elements, a gene or genes of interest, and other components known to those skilled in the art to provide a complete shuttle vector harboring the insulated gene(s) as a transgene, see e.g., U.S. Patent No. 5,610,053. Another method involves directly injecting a transgene into the embryo. A third  
10 method involves the use of embryonic stem cells. Examples of animals into which the TNFRSF1A isogenes may be introduced include, but are not limited to, mice, rats, other rodents, and nonhuman primates (see "The Introduction of Foreign Genes into Mice" and the cited references therein, In: Recombinant DNA, Eds. J.D. Watson, M. Gilman, J. Witkowski, and M. Zoller; W.H. Freeman and Company, New York, pages 254-272). Transgenic animals stably expressing a human TNFRSF1A isogene and producing the encoded human TNFRSF1A protein can be used as biological models for studying diseases related to abnormal TNFRSF1A expression and/or activity, and for screening and assaying various candidate drugs, compounds, and treatment regimens to reduce the symptoms or effects of these diseases.

An additional embodiment of the invention relates to pharmaceutical compositions for treating disorders affected by expression or function of a novel TNFRSF1A isogene described herein. The pharmaceutical composition may comprise any of the following active ingredients: a polynucleotide comprising one of these novel TNFRSF1A isogenes; an antisense oligonucleotide directed against one of the novel TNFRSF1A isogenes, a polynucleotide encoding such an antisense oligonucleotide, or another compound which inhibits expression of a novel TNFRSF1A isogene described herein.  
25 Preferably, the composition contains the active ingredient in a therapeutically effective amount. By therapeutically effective amount is meant that one or more of the symptoms relating to disorders affected by expression or function of a novel TNFRSF1A isogene is reduced and/or eliminated. The composition also comprises a pharmaceutically acceptable carrier, examples of which include, but are not limited to, saline, buffered saline, dextrose, and water. Those skilled in the art may employ a  
30 formulation most suitable for the active ingredient, whether it is a polynucleotide, oligonucleotide, protein, peptide or small molecule antagonist. The pharmaceutical composition may be administered alone or in combination with at least one other agent, such as a stabilizing compound. Administration of the pharmaceutical composition may be by any number of routes including, but not limited to oral, intravenous, intramuscular, intra-arterial, intramedullary, intrathecal, intraventricular, intradermal,  
35 transdermal, subcutaneous, intraperitoneal, intranasal, enteral, topical, sublingual, or rectal. Further details on techniques for formulation and administration may be found in the latest edition of Remington's Pharmaceutical Sciences (Maack Publishing Co., Easton, PA).

For any composition, determination of the therapeutically effective dose of active ingredient and/or the appropriate route of administration is well within the capability of those skilled in the art. For example, the dose can be estimated initially either in cell culture assays or in animal models. The animal model may also be used to determine the appropriate concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans. The exact dosage will be determined by the practitioner, in light of factors relating to the patient requiring treatment, including but not limited to severity of the disease state, general health, age, weight and gender of the patient, diet, time and frequency of administration, other drugs being taken by the patient, and tolerance/response to the treatment.

Any or all analytical and mathematical operations involved in practicing the methods of the present invention may be implemented by a computer. In addition, the computer may execute a program that generates views (or screens) displayed on a display device and with which the user can interact to view and analyze large amounts of information relating to the TNFRSF1A gene and its genomic variation, including chromosome location, gene structure, and gene family, gene expression data, polymorphism data, genetic sequence data, and clinical data population data (e.g., data on ethnogeographic origin, clinical responses, genotypes, and haplotypes for one or more populations). The TNFRSF1A polymorphism data described herein may be stored as part of a relational database (e.g., an instance of an Oracle database or a set of ASCII flat files). These polymorphism data may be stored on the computer's hard drive or may, for example, be stored on a CD-ROM or on one or more other storage devices accessible by the computer. For example, the data may be stored on one or more databases in communication with the computer via a network.

Preferred embodiments of the invention are described in the following examples. Other embodiments within the scope of the claims herein will be apparent to one skilled in the art from consideration of the specification or practice of the invention as disclosed herein. It is intended that the specification, together with the examples, be considered exemplary only, with the scope and spirit of the invention being indicated by the claims which follow the examples.

## EXAMPLES

The Examples herein are meant to exemplify the various aspects of carrying out the invention and are not intended to limit the scope of the invention in any way. The Examples do not include detailed descriptions for conventional methods employed, such as in the performance of genomic DNA isolation, PCR and sequencing procedures. Such methods are well-known to those skilled in the art and are described in numerous publications, for example, Sambrook, Fritsch, and Maniatis, "Molecular Cloning: A Laboratory Manual", 2<sup>nd</sup> Edition, Cold Spring Harbor Laboratory Press, USA, (1989).

35

### EXAMPLE 1

This example illustrates examination of various regions of the TNFRSF1A gene for

polymorphic sites.

#### Amplification of Target Regions

The following target regions of the TNFRSF1A gene were amplified using 'tailed' PCR primers,  
5 each of which includes a universal sequence forming a noncomplementary 'tail' attached to the 5' end of  
each unique sequence in the PCR primer pairs. The universal 'tail' sequence for the forward PCR  
primers comprises the sequence 5'-TGTAAAACGACGCCAGT-3' (SEQ ID NO:39) and the  
universal 'tail' sequence for the reverse PCR primers comprises the sequence 5'-  
AGGAAACAGCTATGACCAT-3' (SEQ ID NO:40). The nucleotide positions of the first and last  
10 nucleotide of the forward and reverse primers for each region amplified are presented below and  
correspond to positions in SEQ ID NO:1 (Figure 1).

#### PCR Primer Pairs

	Fragment No.	Forward Primer	Reverse Primer	PCR Product
15	Fragment 1	2920-2940	complement of 3495-3473	576 nt
16	Fragment 2	3270-3292	complement of 3858-3837	589 nt
17	Fragment 3	3641-3662	complement of 4210-4190	570 nt
18	Fragment 4	11417-11440	complement of 11915-11896	499 nt
19	Fragment 5	11797-11820	complement of 12308-12286	512 nt
20	Fragment 6	12178-12198	complement of 12625-12604	448 nt
21	Fragment 7	12548-12569	complement of 12926-12904	379 nt
22	Fragment 8	14634-14656	complement of 15120-15100	487 nt
23	Fragment 9	14951-14974	complement of 15408-15386	458 nt
24	Fragment 10	15388-15410	complement of 15710-15688	323 nt
25	Fragment 11	15629-15650	complement of 16053-16032	425 nt
26	Fragment 12	15818-15837	complement of 16274-16255	457 nt
27	Fragment 13	15945-15964	complement of 16476-16457	532 nt
28	Fragment 14	16229-16248	complement of 16768-16749	540 nt

30

These primer pairs were used in PCR reactions containing genomic DNA isolated from immortalized cell lines for each member of the Index Repository. The PCR reactions were carried out under the following conditions:

	Reaction volume	= 10 $\mu$ l
35	10 x Advantage 2 Polymerase reaction buffer (Clontech)	= 1 $\mu$ l
	100 ng of human genomic DNA	= 1 $\mu$ l
	10 mM dNTP	= 0.4 $\mu$ l
	Advantage 2 Polymerase enzyme mix (Clontech)	= 0.2 $\mu$ l
	Forward Primer (10 $\mu$ M)	= 0.4 $\mu$ l
40	Reverse Primer (10 $\mu$ M)	= 0.4 $\mu$ l
	Water	= 6.6 $\mu$ l

45

Amplification profile:

97°C - 2 min. 1 cycle

97°C - 15 sec.

70°C - 45 sec.

10 cycles.

72°C - 45 sec.

97°C - 15 sec.  
5 64°C - 45 sec. 35 cycles  
72°C - 45 sec.

Sequencing of PCR Products

The PCR products were purified using a Whatman/Polyfiltronics 100 µl 384 well unifilter plate  
10 essentially according to the manufacturers protocol. The purified DNA was eluted in 50 µl of distilled water. Sequencing reactions were set up using Applied Biosystems Big Dye Terminator chemistry essentially according to the manufacturers protocol. The purified PCR products were sequenced in both directions using the appropriate universal 'tail' sequence as a primer. Reaction products were purified by isopropanol precipitation, and run on an Applied Biosystems 3700 DNA Analyzer.

Analysis of Sequences for Polymorphic Sites

Sequence information for a minimum of 80 humans was analyzed for the presence of polymorphisms using the Polyphred program (Nickerson et al., *Nucleic Acids Res.* 14:2745-2751, 1997). The presence of a polymorphism was confirmed on both strands. The polymorphisms and their locations in the TNFRSF1A reference genomic sequence (SEQ ID NO:1) are listed in Table 3 below.

Table 3. Polymorphic Sites Identified in the TNFRSF1A Gene

	Polymorphic Site Number	PolyId <sup>a</sup>	Nucleotide Position	Reference Allele	Variant Allele	CDS Variant Position	AA Variant
5	PS1	14893290	3102	G	T		
	PS2 <sup>R</sup>	14628027	3409	T	G		
	PS3 <sup>R</sup>	14628285	3438	A	G		
10	PS4	14896363	3603	C	G		
	PS5 <sup>R</sup>	12629393	4054	A	G		
	PS6 <sup>R</sup>	14899006	4082	G	A		
	PS7 <sup>R</sup>	14628618	11998	C	T	224	P75L
	PS8 <sup>R</sup>	14907497	12356	G	A	362	R121Q
15	PS9 <sup>R</sup>	14628786	12397	T	C	403	Y135H
	PS10 <sup>R</sup>	14628882	12489	C	T		
	PS11 <sup>R</sup>	12629390	12653	T	C		
	PS12	14912649	14824	G	A		
20	PS13 <sup>R</sup>	12629387	14990	A	G		
	PS14	14913232	15089	C	T		
	PS15	14913234	15093	C	T		
25	PS16 <sup>R</sup>	14629167	15529	T	C		
	PS17	14904430	15932	G	A	935	R312K
	PS18	14900521	16165	G	A		

<sup>a</sup>PolyId is a unique identifier assigned to each PS by Genaissance Pharmaceuticals, Inc.

<sup>R</sup>Previously identified in the literature.

#### EXAMPLE 2

This example illustrates analysis of the TNFRSF1A polymorphisms identified in the Index Repository for human genotypes and haplotypes.

The different genotypes containing these polymorphisms that were observed in unrelated members of the reference population are shown in Table 4 below, with the haplotype pair indicating the combination of haplotypes determined for the individual using the haplotype derivation protocol described below. In Table 4, homozygous positions are indicated by one nucleotide and heterozygous positions are indicated by two nucleotides. Missing nucleotides in any given genotype in Table 4 were inferred based on linkage disequilibrium and/or Mendelian inheritance.

TABLE 4 (PART1). GENOTYPES AND HAPLOTYPE PAIRS OBSERVED FOR TNFRSF1A GENE

GENOTYPE NUMBER	POLYMORPHIC SITES										HAP	PAIR
	PS1	PS2	PS3	PS4	PS5	PS6	PS7	PS8	PS9	PS10		
5	1	G	G	A	C	G	G	C	G	T	C	12
	2	G	T	A	C	A	G	C	G	T	C	22
	3	G	G	A	C	A	G	C	G	T	C	2
	4	G	T	A	C	A	G	C	G	T	C	22
10	5	G	G	A	C	G	G	C	G	T	C	12
	6	G	G	A	C	A	G	C	G	T	C	2
	7	G	T	A	C	A	G	C	G	T	C/T	22
	8	G	G	A	C	A/G	G	C	G	T	C	2
	9	G	G/T	A	C	A	G	C	G	T	C	2
15	10	G	G	A	C	A/G	G	C/T	G	T	C	3
	11	G	G	A/G	C	G/A	G	C	G	T	C	12
	12	G	T/G	A	C	A/G	G	C	G/A	T	C	22
	13	G	G	A	C	A/G	G	C	G	T/C	C	2
	14	G	G/T	A	C	A	G	C	G	T	C	3
20	15	G	G	A/G	C	A	G	C	G	T	C	2
	16	G	G	A/G	C	G/A	G	C/T	G	T	C	12
	17	G	G/T	A	C	A	G	C	G	T	C	2
	18	G	T/G	A	C	A	G	C	G	T	C	22
	19	G	T	A	C/G	A	G	C	G	T	C	22
25	20	G	G/T	A	C/G	G/A	G	C	G	T	C	12
	21	G	G/T	A	C	G	G	C	G	T	C	12
	22	G	G	A	C	G	G	C	G	T	C	12
	23	G	G	A/G	C	A	G	C	G	T	C	3
	24	G	T/G	A/G	C	A	G	C	G	T	C	22
30	25	G/T	G	A/G	C	A	G	C	G	T	C	3
	26	G	T/G	A	C	A/G	G	C	G	T	C	22
	27	G	G	A/G	C	A	G	C	G	T	C	2
	28	G	G/T	A/G	C	A	G	C	G	T	C	2
	29	G	T/G	A	C	A/G	G	C	G	T	C	22
35	30	G	G	A	C	G/A	G	C	G	T	C	12
	31	G	T/G	A	C	A	G	C	G	T	C	22
	32	G	T	A	C	A	G/A	C	G	T	C	22
	33	G	T/G	A	C	A/G	G	C	G	T	C	22
40	34	G	G	A	C	G/A	G	C	G	T	C	12
	35	G	G	A	C	G/A	G	C	G	T	C	12
	36	G	G	A	C	G/A	G	C	G	T	C	12
	37	G	G	A	C	G/A	G	T/C	G	T	C	14
	38	G	G	G/A	C	A	G	C	G	T	C	16

TABLE 4 (PART2). GENOTYPES AND HAPLOTYPE PAIRS OBSERVED FOR TNFRSF1A GENE

GENOTYPE NUMBER	POLYMORPHIC SITES								HAP	PAIR	
	PS11	PS12	PS13	PS14	PS15	PS16	PS17	PS18			
5	1	C	G	G	C	C	T	G	12	12	
	2	T	G	A	C	C	T	G	22	22	
	3	C	G	A	C	C	C	G	2	2	
	4	T/C	G	A/G	C	C	T	G	22	20	
10	5	C	G	G/A	C	C	T/C	G	12	10	
	6	C	G/A	A	C	C	C	G	2	1	
	7	T	G	A	C	C	T	G	22	23	
	8	C	G	A	C	C	C/T	G	2	11	
15	9	C	G	A	C	C	C/T	G/A	2	19	
	10	C	G	A/G	C	C	T	G	3	14	
	11	C	G	G/A	C	C	T/C	G	12	15	
	12	T/C	G	A/G	C	C	T	G	22	8	
20	13	C	G	A	C	C	C/T	G	2	9	
	14	C/T	G	A	C	C	T/C	G	3	21	
	15	C	G	A	C	C	C	G	2	15	
	16	C	G	G/A	C	C	T/C	G	12	17	
25	17	C/T	G	A	C	C	C	G	2	21	
	18	T/C	G	A	C	C	T	G	22	3	
	19	T	G	A	C	C	T	G	22	25	
	20	C/T	G	G/A	C	C	T	G	12	25	
30	21	C/T	G	G/A	C	C	T	G	12	24	
	22	C/T	G	G/A	C	C	T	G	12	13	
	23	C	G	A	C	C	T	G	3	16	
	24	T/C	G	A	C	C	T	G	22	16	
35	25	C	G	A	C	C	T	G	G/A	3	27
	26	T/C	G	A	C	C	T/C	G	22	10	
	27	C	G	A	C	C	C/T	G	2	16	
	28	C	G	A	C	C	C	G	2	26	
40	29	T/C	G	A	C	C	T	G	22	11	
	30	C	G	G	C	C	T	G	12	7	
	31	T/C	G	A	C	C	T/C	G	22	2	
	32	T	G	A	C	C	T	G	22	18	
45	33	T/C	G	A/G	C	C	T	G	22	12	
	34	C	G	G/A	C/T	C	T/C	G	12	5	
	35	C	G	G/A	C	C	T	G	12	3	
	36	C	G	G/A	C	C	T/C	G	12	2	
50	37	C	G	G	C	C	T/C	G	14	6	
	38	C	G	A	C	C/T	T/C	G	16	4	

The haplotype pairs shown in Table 4 were estimated from the unphased genotypes using a

computer-implemented extension of Clark's algorithm (Clark, A.G. 1990 *Mol Bio Evol* 7, 111-122) for assigning haplotypes to unrelated individuals in a population sample, as described in PCT/US01/12831, filed April 18, 2001. In this method, haplotypes are assigned directly from individuals who are homozygous at all sites or heterozygous at no more than one of the variable sites. This list of haplotypes is then used to deconvolute the unphased genotypes in the remaining (multiply heterozygous) individuals. In the present analysis, the list of haplotypes was augmented with haplotypes obtained from two families (one three-generation Caucasian family and one two-generation

African-American family).

By following this protocol, it was determined that the Index Repository examined herein and, by extension, the general population contains the 27 human TNFRSF1A haplotypes shown in Table 5 below.

5 An TNFRSF1A isogene defined by a full-haplotype shown in Table 5 below comprises the regions of the SEQ ID NOS indicated in Table 5, with their corresponding set of polymorphic locations and identities, which are also set forth in Table 5.

Table 5. Haplotypes of the TNFRSF1A Gene

HAPLOTYPE	NUMBER <sup>A</sup>	PS <sup>B</sup>	PS	SEQ ID	REGION								
1	2	3	4	5	6	7	8	9	10	NUMBER	POSITION <sup>C</sup>	NO. <sup>D</sup>	EXAMINED <sup>E</sup>
G	G	G	G	G	G	G	G	G	G	1	3102/30	1/41	2920-4210
G	G	G	G	G	G	G	G	G	G	2	3409/150	1/41	2920-4210
A	A	A	A	A	A	A	A	A	A	3	3438/270	1/41	2920-4210
C	C	C	C	C	C	C	C	C	C	4	3603/390	1/41	2920-4210
A	A	A	A	A	A	A	G	G	G	5	4054/510	1/41	2920-4210
G	G	G	G	G	G	G	G	G	G	6	4082/630	1/41	2920-4210
C	C	C	C	C	C	C	C	C	C	7	11998/750	1/41	11417-12926
G	G	G	G	G	G	G	A	G	G	8	12356/870	1/41	11417-12926
T	T	T	T	T	T	T	C	T	T	9	12397/990	1/41	11417-12926
C	C	C	C	C	C	C	C	C	C	10	12489/1110	1/41	11417-12926
C	C	C	C	C	C	C	C	C	C	11	12653/1230	1/41	11417-12926
A	G	G	G	G	G	G	G	G	G	12	14824/1350	1/41	14634-16768
A	A	A	A	A	G	G	G	A	A	13	14990/1470	1/41	14634-16768
C	C	C	C	T	C	C	C	C	C	14	15089/1590	1/41	14634-16768
C	C	C	T	C	C	C	C	C	C	15	15093/1710	1/41	14634-16768
C	C	T	C	C	C	T	T	T	C	16	15529/1830	1/41	14634-16768
G	G	G	G	G	G	G	G	G	G	17	15932/1950	1/41	14634-16768
G	G	G	G	G	G	G	G	G	G	18	16165/2070	1/41	14634-16768
HAPLOTYPE	NUMBER <sup>A</sup>	PS <sup>B</sup>	PS	SEQ ID	REGION								
11	12	13	14	15	16	17	18	19	20	NUMBER	POSITION <sup>C</sup>	NO. <sup>D</sup>	EXAMINED <sup>E</sup>
G	G	G	G	G	G	G	G	G	G	1	3102/30	1/41	2920-4210
G	G	G	G	G	G	G	T	T	T	2	3409/150	1/41	2920-4210
A	A	A	A	G	G	G	A	A	A	3	3438/270	1/41	2920-4210
C	C	C	C	C	C	C	C	C	C	4	3603/390	1/41	2920-4210
G	G	G	G	A	A	A	A	A	A	5	4054/510	1/41	2920-4210
G	G	G	G	G	G	G	A	G	G	6	4082/630	1/41	2920-4210
C	C	C	T	C	C	T	C	C	C	7	11998/750	1/41	11417-12926
G	G	G	G	G	G	G	G	G	G	8	12356/870	1/41	11417-12926
T	T	T	T	T	T	T	T	T	T	9	12397/990	1/41	11417-12926
C	C	C	C	C	C	C	C	C	C	10	12489/1110	1/41	11417-12926
C	C	T	C	C	C	C	T	C	C	11	12653/1230	1/41	11417-12926
G	G	G	G	G	G	G	G	G	G	12	14824/1350	1/41	14634-16768
A	G	A	G	A	A	A	A	A	G	13	14990/1470	1/41	14634-16768
C	C	C	C	C	C	C	C	C	C	14	15089/1590	1/41	14634-16768
C	C	C	C	C	C	C	C	C	C	15	15093/1710	1/41	14634-16768
T	T	T	T	C	T	C	T	T	T	16	15529/1830	1/41	14634-16768
G	G	G	G	G	G	G	G	G	A	17	15932/1950	1/41	14634-16768
G	G	G	G	G	G	G	G	G	G	18	16165/2070	1/41	14634-16768

TABLE 5 (continued). HAPLOTYPES OF THE TNFRSF1A GENE

	HAPLOTYPE NUMBER <sup>A</sup>							PS <sup>B</sup>	PS	SEQ ID NO. <sup>D</sup>	REGION
5	21	22	23	24	25	26	27	NUMBER	POSITION <sup>C</sup>		EXAMINED <sup>E</sup>
	G	G	G	G	G	G	T	1	3102/30	1/41	2920-4210
	T	T	T	T	T	T	G	2	3409/150	1/41	2920-4210
	A	A	A	A	A	G	G	3	3438/270	1/41	2920-4210
	C	C	C	C	G	C	C	4	3603/390	1/41	2920-4210
	A	A	A	G	A	A	A	5	4054/510	1/41	2920-4210
10	G	G	G	G	G	G	G	6	4082/630	1/41	2920-4210
	C	C	C	C	C	C	C	7	11998/750	1/41	11417-12926
	G	G	G	G	G	G	G	8	12356/870	1/41	11417-12926
	T	T	T	T	T	T	T	9	12397/990	1/41	11417-12926
	C	C	T	C	C	C	C	10	12489/1110	1/41	11417-12926
	T	T	T	T	T	C	C	11	12653/1230	1/41	11417-12926
15	G	G	G	G	G	G	G	12	14824/1350	1/41	14634-16768
	A	A	A	A	A	A	A	13	14990/1470	1/41	14634-16768
	C	C	C	C	C	C	C	14	15089/1590	1/41	14634-16768
	C	C	C	C	C	C	C	15	15093/1710	1/41	14634-16768
	C	T	T	T	T	C	T	16	15529/1830	1/41	14634-16768
	G	G	G	G	G	G	G	17	15932/1950	1/41	14634-16768
20	G	G	G	G	G	A		18	16165/2070	1/41	14634-16768

<sup>A</sup>Alleles for TNFRSF1A haplotypes are presented 5' to 3' in each column;<sup>B</sup>PS = polymorphic site;<sup>C</sup>Position of PS within the indicated SEQ ID NO, with the 1<sup>st</sup> position number referring to the first SEQ ID NO and the 2<sup>nd</sup> position number referring to the 2<sup>nd</sup> SEQ ID NO;<sup>D</sup>1<sup>st</sup> SEQ ID NO refers to Figure 1, with the two alternative allelic variants of each polymorphic site indicated by the appropriate nucleotide symbol; 2<sup>nd</sup> SEQ ID NO is a modified version of the 1<sup>st</sup> SEQ ID NO that comprises the context sequence of each polymorphic site, PS1-PS18, to facilitate electronic searching of the haplotypes;<sup>E</sup>Region examined represents the nucleotide positions defining the start and stop positions within the 1<sup>st</sup> SEQ ID NO of the sequenced region.

SEQ ID NO:1 refers to Figure 1, with the two alternative allelic variants of each polymorphic site indicated by the appropriate nucleotide symbol. SEQ ID NO:41 is a modified version of SEQ ID NO:1 that shows the context sequence of each of PS1-PS18 in a uniform format to facilitate electronic searching of the TNFRSF1A haplotypes. For each polymorphic site, SEQ ID NO:41 contains a block of 60 bases of the nucleotide sequence encompassing the centrally-located polymorphic site at the 30<sup>th</sup> position, followed by 60 bases of unspecified sequence to represent that each polymorphic site is separated by genomic sequence whose composition is defined elsewhere herein.

Table 6 below shows the percent of chromosomes characterized by a given TNFRSF1A haplotype for all unrelated individuals in the Index Repository for which haplotype data was obtained. The percent of these unrelated individuals who have a given TNFRSF1A haplotype pair is shown in Table 7. In Tables 6 and 7, the "Total" column shows this frequency data for all of these unrelated individuals, while the other columns show the frequency data for these unrelated individuals categorized according to their self-identified ethnogeographic origin. Abbreviations used in Tables 6 and 7 are AF = African Descent, AS = Asian, CA = Caucasian, HL = Hispanic-Latino, and AM = Native American.

Table 6 Frequency of Observed TNFRSF1A Haplotypes In Unrelated Individuals

HAP No.	HAP ID	Total	CA	AF	AS	HL	AM
5	1 20269284	0.61	0.0	0.0	0.0	2.78	0.0
	2 20269269	20.12	7.14	15.0	37.5	22.22	16.67
	3 20269270	4.88	2.38	12.5	0.0	5.56	0.0
10	4 20269281	0.61	0.0	2.5	0.0	0.0	0.0
	5 20269279	0.61	2.38	0.0	0.0	0.0	0.0
	6 20269280	0.61	0.0	2.5	0.0	0.0	0.0
15	7 20269293	0.61	2.38	0.0	0.0	0.0	0.0
	8 20269283	0.61	2.38	0.0	0.0	0.0	0.0
	9 20269282	0.61	0.0	0.0	2.5	0.0	0.0
20	10 20269272	2.44	0.0	2.5	0.0	8.33	0.0
	11 20269286	1.22	2.38	0.0	0.0	2.78	0.0
	12 20269268	22.56	38.1	15.0	17.5	13.89	50.0
25	13 20269287	0.61	0.0	2.5	0.0	0.0	0.0
	14 20269277	1.22	0.0	5.0	0.0	0.0	0.0
	15 20269273	1.22	0.0	2.5	0.0	2.78	0.0
30	16 20269271	4.27	0.0	15.0	0.0	2.78	0.0
	17 20269290	0.61	0.0	2.5	0.0	0.0	0.0
	18 20269291	0.61	0.0	0.0	2.5	0.0	0.0
35	19 20269288	0.61	0.0	0.0	0.0	0.0	16.67
	20 20269289	0.61	0.0	0.0	0.0	2.78	0.0
	21 20269274	1.22	2.38	0.0	0.0	2.78	0.0
40	22 20269267	29.27	33.33	15.0	40.0	30.56	16.67
	23 20269292	0.61	0.0	0.0	0.0	2.78	0.0
	24 20269278	0.61	2.38	0.0	0.0	0.0	0.0
45	25 20269276	1.22	4.76	0.0	0.0	0.0	0.0
	26 20269275	1.22	0.0	5.0	0.0	0.0	0.0
	27 20269285	0.61	0.0	2.5	0.0	0.0	0.0

Table 7. Frequency of Observed TNFRSF1A Haplotype Pairs In Unrelated Individuals

	HAP1	HAP2	Total	CA	AF	AS	HL	AM
5	12	12	4.88	9.52	5.0	0.0	0.0	33.33
	22	22	6.1	4.76	5.0	15.0	0.0	0.0
	2	2	3.66	0.0	0.0	15.0	0.0	0.0
	22	20	1.22	0.0	0.0	0.0	5.56	0.0
	12	10	1.22	0.0	0.0	0.0	5.56	0.0
10	2	1	1.22	0.0	0.0	0.0	5.56	0.0
	22	23	1.22	0.0	0.0	0.0	5.56	0.0
	2	11	1.22	0.0	0.0	0.0	5.56	0.0
	2	19	1.22	0.0	0.0	0.0	0.0	33.33
	3	14	1.22	0.0	5.0	0.0	0.0	0.0
15	12	15	1.22	0.0	5.0	0.0	0.0	0.0
	22	8	1.22	4.76	0.0	0.0	0.0	0.0
	2	9	1.22	0.0	0.0	5.0	0.0	0.0
	3	21	1.22	4.76	0.0	0.0	0.0	0.0
	2	15	1.22	0.0	0.0	0.0	5.56	0.0
20	12	17	1.22	0.0	5.0	0.0	0.0	0.0
	2	21	1.22	0.0	0.0	0.0	5.56	0.0
	22	3	1.22	0.0	0.0	0.0	5.56	0.0
	22	25	1.22	4.76	0.0	0.0	0.0	0.0
	12	25	1.22	4.76	0.0	0.0	0.0	0.0
25	12	24	1.22	4.76	0.0	0.0	0.0	0.0
	12	13	1.22	0.0	5.0	0.0	0.0	0.0
	3	16	3.66	0.0	15.0	0.0	0.0	0.0
	22	16	1.22	0.0	5.0	0.0	0.0	0.0
	3	27	1.22	0.0	5.0	0.0	0.0	0.0
30	22	10	3.66	0.0	5.0	0.0	11.11	0.0
	2	16	2.44	0.0	5.0	0.0	5.56	0.0
	2	26	2.44	0.0	10.0	0.0	0.0	0.0
	22	11	1.22	4.76	0.0	0.0	0.0	0.0
	12	7	1.22	4.76	0.0	0.0	0.0	0.0
35	22	2	14.63	9.52	10.0	25.0	16.67	0.0
	22	18	1.22	0.0	0.0	5.0	0.0	0.0
	22	12	18.29	33.33	0.0	20.0	16.67	33.33
	12	5	1.22	4.76	0.0	0.0	0.0	0.0
	12	3	1.22	0.0	0.0	0.0	5.56	0.0
40	12	2	6.1	4.76	5.0	15.0	0.0	0.0
	14	6	1.22	0.0	5.0	0.0	0.0	0.0
	16	4	1.22	0.0	5.0	0.0	0.0	0.0

The size and composition of the Index Repository were chosen to represent the genetic diversity across and within four major population groups comprising the general United States population. For example, as described in Table 1 above, this repository contains approximately equal sample sizes of African-descent, Asian-American, European-American, and Hispanic-Latino population groups. Almost all individuals representing each group had all four grandparents with the same ethnogeographic background. The number of unrelated individuals in the Index Repository provides a sample size that is sufficient to detect SNPs and haplotypes that occur in the general population with high statistical certainty. For instance, a haplotype that occurs with a frequency of 5% in the general

population has a probability higher than 99.9% of being observed in a sample of 80 individuals from the general population. Similarly, a haplotype that occurs with a frequency of 10% in a specific population group has a 99% probability of being observed in a sample of 20 individuals from that population group. In addition, the size and composition of the Index Repository means that the relative frequencies determined therein for the haplotypes and haplotype pairs of the TNFRSF1A gene are likely to be similar to the relative frequencies of these TNFRSF1A haplotypes and haplotype pairs in the general U.S. population and in the four population groups represented in the Index Repository. The genetic diversity observed for the three Native Americans is presented because it is of scientific interest, but due to the small sample size it lacks statistical significance.

10 In view of the above, it will be seen that the several advantages of the invention are achieved  
and other advantageous results attained.

As various changes could be made in the above methods and compositions without departing from the scope of the invention, it is intended that all matter contained in the above description and shown in the accompanying drawings shall be interpreted as illustrative and not in a limiting sense.

All references cited in this specification, including patents and patent applications, are hereby incorporated in their entirety by reference. The discussion of references herein is intended merely to summarize the assertions made by their authors and no admission is made that any reference constitutes prior art. Applicants reserve the right to challenge the accuracy and pertinency of the cited references.